

(19)



(11)

EP 1 192 247 B9

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 B1)**Corrections, see****Description Paragraph(s) 139**

(51) Int Cl.:

C12N 9/12 (2006.01) **A61K 38/45** (2006.01)**C07K 16/18** (2006.01) **C07K 16/40** (2006.01)

(86) International application number:

PCT/AU2000/000457

(87) International publication number:

WO 2000/070028 (23.11.2000 Gazette 2000/47)

(48) Corrigendum issued on:

31.10.2007 Bulletin 2007/44

(45) Date of publication and mention of the grant of the patent:

12.04.2006 Bulletin 2006/15(21) Application number: **00926537.2**(22) Date of filing: **12.05.2000**(54) **SPHINGOSINE KINASE ENZYME**

SPHINGOSINEKINASE

ENZYME SPHINGOSINE KINASE

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**(74) Representative: **Brasnett, Adrian Hugh et al****Mewburn Ellis LLP****York House****23 Kingsway****London WC2B 6HP (GB)**(30) Priority: **13.05.1999 AU PQ033999****08.07.1999 AU PQ150499**

(56) References cited:

WO-A-00/05365**WO-A-00/52173****WO-A-00/55332****AU-A- 4 097 999**

(43) Date of publication of application:

03.04.2002 Bulletin 2002/14(73) Proprietor: **Johnson & Johnson Pharmaceutical****Research and****Development LLC****Raritan,****New Jersey 08869 (US)**

- **NAVA V E ET AL:** "Functional characterization of human sphingosine kinase-1" **FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 473, no. 1, 4 May 2000 (2000-05-04), pages 81-84, XP004337110 ISSN: 0014-5793**

(72) Inventors:

- **PITSON, Stuart, Maxwell**

Norwood, South Australia 5067 (AU)

- **WATTENBERG, Brian, Wolff**

Belair, South Australia 5052 (AU)

- **XIA, Pu**

Magill, South Australia 5072 (AU)

- **D'ANDREA, Richard, James**

Stonyfell, South Australia 5066 (AU)

- **GAMBLE, Jennifer, Ruth**

Stirling, South Australia 5152 (AU)

- **VADAS, Mathew, Alexander**

Stirling, South Australia 5152 (AU)

- **KOHAMA T. ET AL.:** 'Molecular cloning and functional characterisation of murine sphingosine kinase' **THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 37, 11 September 1998, pages 23722 - 23728**

- **SU Y. ET AL.:** 'Sphingosine 1-phosphate, a novel signaling molecule, stimulates DNA binding activity of AP-1 in quiescent swiss 3T3 fibroblasts' **THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 269, no. 23, 10 June 1994, pages 16512 - 16517**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 192 247 B9

- KOLESNICK R.N. ET AL.: 'Characterization of a ceramide kinase activity from human leukemia (HL-60) cells' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 265, no. 31, 05 November 1990, pages 18803 - 18808
- HINKOVSKA-GALCHEVA V.T. ET AL.: 'The formation of ceramide-1-phosphate during neutrophil phagocytosis and its role in liposome fusion' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 50, 11 December 1998, pages 33203 - 33209

Description**FIELD OF THE INVENTION**

[0001] The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences, encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.

BACKGROUND OF THE INVENTION

[0002] Bibliographic details of the publications referred to by author in this specification are collected alphabetically at the end of the description.

[0003] Sphingosine kinase is a key regulatory enzyme in a variety of cellular responses. Its activity can affect inflammation, apoptosis and cell proliferation, and thus it is an important target for therapeutic intervention.

[0004] Sphingosine-1-phosphate is known to be an important second messenger in signal transduction (Meyer *et al.*, 1997). It is mitogenic in various cell types (Alessenko, 1998; Spiegel *et al.*, 1998) and appears to trigger a diverse range of important regulatory pathways including; prevention of ceramide-induced apoptosis (Culliver *et al.*, 1996), mobilisation of intracellular calcium by an IP₃-independent pathway, stimulation of DNA synthesis, activation of mitogen-activated protein (MAP) kinase pathway, activation of phospholipase D, and regulation of cell motility (for reviews see Meyer *et al.*, 1997; Spiegel *et al.*, 1998; Igarashi, 1997).

[0005] Recent studies (Xia *et al.*, 1998) have shown that sphingosine-1-phosphate is an obligatory signalling intermediate in the inflammatory response of vascular endothelial cells to tumour necrosis factor- α (TNF α). In spite of its obvious importance, very little is known of the mechanisms that control cellular sphingosine-1-phosphate levels. It is known that sphingosine-1-phosphate levels in the cell are mediated largely by its formation from sphingosine by sphingosine kinase, and to a lesser extent by its degradation by endoplasmic reticulum-associated sphingosine-1-phosphate lyase and sphingosine-1-phosphate phosphatase (Spiegel *et al.*, 1998). Basal levels of sphingosine-1-phosphate in the cell are generally low, but can increase rapidly and transiently when cells are exposed to mitogenic agents. This response appears correlated with an increase in sphingosine kinase activity in the cytosol and can be prevented by addition of the sphingosine kinase inhibitory molecules *N,N*-dimethylsphingosine and DL-*threo*-dihydrosphingosine. This indicates that sphingosine kinase is an important molecule responsible for regulating cellular sphingosine-1-phosphate levels. This places sphingosine kinase in a central and obligatory role in mediating the effects attributed to sphingosine-1-phosphate in the cell.

[0006] Accordingly, there is a need to identify and clone novel sphingosine kinase molecules to facilitate the progression towards the more sensitive control of intracellular signal transduction via, for example, the elucidation of the mechanism controlling the expression and enzymatic activity of sphingosine kinase thereby providing a platform for the development of interventional therapies to regulate the expression or activity of sphingosine kinase. In work leading up to the present invention the inventors have purified and cloned a novel sphingosine kinase molecule.

SUMMARY OF THE INVENTION

[0007] The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography: Each nucleotide or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <11>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (e.g. <400>1. <400>2. etc).

[0008] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0009] One aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding a novel sphingosine kinase protein, the nucleic acid molecule comprising the sequence of SEQ ID NO:1.

[0010] Yet another further aspect of the present invention provides an amino acid sequence set forth in <400>2.

[0011] Yet another further aspect of the present invention relates to the use of a sphingosine kinase antagonist selected from antisense nucleic acids, antibodies, RNA, DNazymes, and RNA aptamers in the manufacture of a medicament for the treatment of a disease characterised by sphingosine kinase activity, such as rheumatoid arthritis, asthma, atherosclerosis, meningitis, multiple sclerosis, septic shock, inflammation, cell proliferation and apoptosis.

[0012] Single and three letter abbreviations used throughout the specification are defined in Table 1.

TABLE 1 Single and three letter amino acid abbreviations

Amino Acid	Three-letter Abbreviation	One-letter Symbol
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	The	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V
Any residue	Xaa	X

BRIEF DESCRIPTION OF THE DRAWINGS

[0013]

Figure 1 is a schematic representation of the 'Sphingomyelin pathway'.

Figure 2 is a graphical representation of anion exchange chromatography of human sphingosine kinase. A, Anion exchange chromatography with Q Sepharose fast flow of the $(\text{NH}_4)_2\text{SO}_4$ precipitated fraction of the human placenta extract showing two peaks of sphingosine kinase activity. Extracts were applied in buffer A and sphingosine kinase activity ($\bullet$) was eluted with a NaCl gradient of 0 to 1M(----). Protein eluted was followed by absorbance at 280 nm (----).

Figure 3 is a graphical representation of the purification of human placenta SK1 by anion exchange chromatography. Purification on a Mono-Q column is enhanced by reapplication and elution from the same column in the presence of ATP. A, The fractions from the calmodulin-Sepharose 4b column containing sphingosine kinase activity were pooled, desalted and applied to the Mono-Q column in buffer A. B, Active fractions from the Mono-Q column were desalted and reappplied to the Mono-Q column in buffer A with 1 mM ATP and 4mM MgCl_2 . In both cases sphingosine kinase activity ($\bullet$) was eluted with a NaCl gradient of 0 to 1M (----), with protein elution followed by absorbance at 280 nm (----).

Figure 4 is an image of SDS-PAGE of purified human placenta sphingosine kinase. The fraction from the Superdex 75 column containing the highest sphingosine kinase activity was applied to SDS-PAGE with silver staining, yielding a single band of 45 kDa.

Figure 5 is a graphical representation of preparative anion exchange chromatography. Only a single chromato-

graphically identified sphingosine kinase isoform is present in HUVEC. Preparative anion exchange chromatography with HiTrap-Q columns of human placenta, HUVEC and TNF α treated HUVEC extracts showing, in HUVEC, the presence of a single sphingosine kinase peak that increases in activity following treatment of cells with TNF α . Cells were harvested, lysed and the soluble extracts applied to the HiTrap-Q column in buffer A. Total sphingosine kinase activity in human placenta, HUVEC and TNF α treated HUVEC extracts were 51, 78 and 136 U/mg protein, respectively. Sphingosine kinase activity (●) was eluted with a NaCl gradient of 0 to 1M (----).

Figure 6 is a schematic representation of the strategy used to clone sphingosine kinase (SPHK) from HUVEC.

Figure 7 is a schematic representation of the nucleotide (<400>1) and deduced amino acid (<400>2) sequences and putative domain structure of human sphingosine kinase. A, cDNA nucleic acid sequence and the deduced amino acid sequence of hSK. Amino acids are numbered from the first methionine residue. The stop codon is indicated by an asterisk. The sphingosine kinase coding region is in capital letters (nucleotides 33-1197), while lower case letters denote untranslated and vector sequence. B, Schematic representation of human sphingosine kinase showing locations of the putative PKC and CKII phosphorylation sites, a possible N-myristoylation site, calcium/calmodulin binding motifs and the region with similarity to the putative DGK catalytic domain.

Figure 8 is a graphical representation of the expression and TNF α stimulation of human sphingosine kinase activity in HEK293 cells. HEK293 cells transiently transfected with either empty pcDNA expression vector alone (A) or pcDNA containing human sphingosine kinase cDNA (B). Transfected cells were either untreated or treated with TNF α for 10 min, harvested and sphingosine kinase activity in cell lysates determined. Data are means of duplicates and are representative of three independent experiments.

Figure 9 is a schematic representation of the sequence comparison of human sphingosine kinase with other known and putative sphingosine kinases. Comparison of the deduced human sphingosine kinase amino acid sequence with the amino acid sequences of the murine (MSK1a and mSK1b; Kohama *et al.*, 1998) and *S. cerevisiae* (LCB4 and LCB5; Nagiec *et al.*, 1998) sphingosine kinases, and EST sequences of putative sphingosine kinases from *S. pombe* and *C. elegans* (Genbank™ accession numbers Z98762 and Z66494, respectively). Although the amino acid sequence similarity to human sphingosine kinase was high (36% identity), the *A. thaliana* putative sphingosine kinase sequence (Genbank™ accession number AL022603) gave relatively poor alignment and for clarity, is not shown. The consensus sequence represents amino acids that are conserved in at least six of the seven aligned sequences, while conservation of structurally similar amino acids are denoted with an asterisk. Multiple sequence alignment was performed with CLUSTALW, and percentage identities to the human sphingosine kinase were determined using the GAP algorithm (Needleman & Wunsch, 1970).

Figure 10 is an image of the expression of recombinant human sphingosine kinase in *E. coli* BL21. *E. coli* BL21 was transformed with the pGEX4-2T human sphingosine kinase expression construct and expression of the GST-SK fusion protein analysed after induction with 100 μ M IPTG. A, Sphingosine kinase activity in uninduced and IPTG induced *E. coli* BL21 cell extracts. B, Coomassie stained SDS-PAGE gel showing GST-SK fusion protein expression in *E. coli* cell lysates. C, Purity of the isolated recombinant human sphingosine kinase. The fraction from the Mono-Q column containing sphingosine kinase activity was applied to SDS-PAGE with silver staining yielding a single band of 45 kDa.

Figure 11 is an image of the purification of recombinant human sphingosine kinase. Calmodulin Sepharose 4B allows the separation of active and inactive enzyme. The GST. SK fusion protein was partially purified using glutathione-Sepharose 4B, cleaved by thrombin and applied to the calmodulin-Sepharose 4B column in Buffer B containing 4 mM CaCl₂. Elution (↓) of the active sphingosine kinase bound to the column was performed with Buffer A containing 2 mM EGTA and 1 M NaCl. A, SDS-PAGE analysis of fractions eluted from the calmodulin-Sepharose 4B column. B, Sphingosine kinase activity (I) in column fractions showing most of the recombinant human sphingosine kinase protein did not bind to the column and displayed no catalytic activity.

Figure 12 is a graphical representation of the physico-chemical properties of the native and recombinant sphingosine kinases. A, pH optima. The effect of pH on SK activity was determined by assaying the activity over the pH range of 4 to 11 in 50 mM buffers (sodium acetate, pH 4.0-5.0; Mes, pH 6.0-7.0; Hepes, pH 7.0-8.2; Tris/HCl, pH 8.2-10.0; Caps, pH 10.0-11.0). B, pH stability. Data shown is the SK activity remaining after preincubation of the enzymes at various pH at 4°C for 5h. C, Temperature stability. Data shown is the SK activity remaining after preincubation of the enzymes at various temperatures (4 to 80°C) for 30 min at pH 7.4 (50mM Tris/HCl containing 10% glycerol, 0.5 M NaCl and 0.05% Triton X-100). D, Metal ion requirement. The various metal ions or EDTA were supplied in the

assay mixture at a final concentration of 10 mM. In all cases the maximum activities of the native (• and filled bars) and recombinant (○ and open bars) sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively. Data are means $\pm$ S.D.

Figure 13 is a graphical representation of the substrate specificity and kinetics of the native and recombinant sphingosine kinases. A, Substrate specificity of the native (filled bars) and recombinant (open bars) sphingosine kinases with sphingosine analogues and other lipids supplied at 100 μ M in 0.25% Triton X-100. The rates of phosphorylation of sphingosine by the native and recombinant Sks were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively. Activity against other potential substrates were expressed relative to the activity against sphingosine. No phosphorylation was observed with DL-*threo*-dihydrosphingosine, *N,N*-dimethylsphingosine, *N,N,N*-trimethylsphingosine, *N*-acetylsphingosine (*C*₂-ceramide), diacylglycerol (1,2-dioctanoyl-sn-glycerol and 1,2-dioleoyl-sn-glycerol), and phosphatidylinositol. B, Substrate kinetics of the recombinant human sphingosine kinase with sphingosine (•) and D-*erythro*-dihydrosphingosine (•) as substrates. C, Kinetics of inhibition of the recombinant human sphingosine kinase with *N,N,N*-trimethylsphingosine at 5 μ M (○) and 25 μ M (▼) and in the absence of *N,N,N*-trimethylsphingosine (•). Inset: Lineweaver-Burk plot. Data are means $\pm$ S.D.

Figure 14 is a graphical representation of the acidic phospholipids which stimulate the activity of the native and recombinant sphingosine kinases. The effect of various phospholipids on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity under standard conditions in the presence of these phospholipids at 10 mol% of Triton X-100. The activities of the native (filled bars) and recombinant (open bars) sphingosine kinases in the absence of phospholipids were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively. PC, phosphatidylcholine; PS, phosphatidylserine; PE, phosphatidylethanolamine; PI phosphatidylinositol; PA, phosphatidic acid. Data are means $\pm$ S.D.

DETAILED DESCRIPTION OF THE INVENTION

[0014] The present invention is predicated, in part, on the purification and cloning of a novel sphingosine kinase molecule. The identification of this novel molecule permits the identification and rational design of a range of products for use in therapy, diagnosis and antibody generation, for example for use in signal transduction. These therapeutic molecules may also act as either antagonists or agonists of sphingosine kinase function and will be useful, *inter alia*, in the modulation of cellular activation in the treatment of disease conditions characterised by unwanted cellular activity.

[0015] Accordingly, one aspect of the present invention provides an isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a novel sphingosine kinase protein or a derivative or mimetic of said sphingosine kinase protein.

[0016] Reference to "sphingosine kinase" should be understood as a reference to the molecule which is, *inter alia*, involved in the generation of sphingosine-1-phosphate during the activation of the sphingosine kinase signalling pathway. Reference to "*sphingosine kinase*" in italicised text should be understood as a reference to the sphingosine kinase nucleic acid molecule. Reference to "sphingosine kinase" in non-italicised text should be understood as a reference to the sphingosine kinase protein molecule.

[0017] More particularly, the present invention provides an isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a human sphingosine kinase protein or a derivative or mimetic of said sphingosine kinase protein.

[0018] In a preferred embodiment, the present invention provides a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>2.

[0019] The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. The percentage similarity may be greater than 50% such as at least 70% or at least 80% or at least 90% or at least 95% or higher.

[0020] Another aspect of the present invention contemplates a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>1.

[0021] Reference herein to a low stringency includes and encompasses from at least about 0% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M

salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions. Stringency may be measured using a range of temperature such as from about 40°C to about 65 °C. Particularly useful stringency conditions are at 42° C.

[0022] More particularly, the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>1.

[0023] The nucleic acid molecule according to this aspect of the present invention corresponds herein to human *sphingosine kinase*. Without limiting the present invention to any one theory or mode of action, the protein encoded by *sphingosine kinase* is a key element in the functioning of the sphingosine kinase, signalling pathway. Sphingosine kinase acts to facilitate the generation of the second messenger, sphingosine-1-phosphate, and may be activated by:

(a) post-translational modifications such as phosphorylation or proteolytic cleavage;

(b) protein-protein interactions such as dimerisation, and G protein-coupled receptor mediated interactions;

(c) translocational events where the enzyme is targeted to an environment that increases catalytic activity or allows access to its substrate.

[0024] The expression product of the human *sphingosine kinase* nucleic acid molecule is human sphingosine kinase. Sphingosine kinase is defined by the amino acid sequence set forth in <400>2. The cDNA sequence for sphingosine kinase is defined by the nucleotide sequence set forth in <400>1. The nucleic acid molecule encoding sphingosine kinase is preferably a sequence of deoxyribonucleic acids such as a cDNA sequence or a genomic sequence. A genomic sequence may also comprise exons and introns. A genomic sequence may also include a promoter region or other regulatory regions.

[0025] Reference herein to sphingosine kinase and *sphingosine kinase* should be understood as a reference to all forms of human sphingosine kinase and *sphingosine kinase*, respectfully, including, for example, any peptide and cDNA isoforms which arise from alternative splicing of *sphingosine kinase* mRNA, mutants or polymorphic variants of *sphingosine kinase* or sphingosine kinase, the post-translation modified form of sphingosine kinase or the non-post-translation modified form of sphingosine kinase. To the extent that it is not specified, reference herein to sphingosine kinase and *sphingosine kinase* includes reference to derivatives, analogues, chemical equivalents and mimetics thereof.

[0026] The protein and/or gene is preferably from the human. However, the protein and/or gene may also be isolated from other animal or non-animal species.

[0027] Derivatives include fragments, parts, portions, mutants, variants and mimetics from natural, synthetic or recombinant sources including fusion proteins. Parts or fragments include, for example, active regions of sphingosine kinase. Derivatives may be derived from insertion, deletion or substitution of amino acids. Amino acid insertional derivatives include amino and/or carboxylic terminal fusions as well as intrasequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterized by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. An example of substitutional amino acid variants are conservative amino acid substitutions. Conservative amino acid substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Additions to amino acid sequences including fusions with other peptides, polypeptides or proteins.

[0028] Chemical and functional equivalents of *sphingosine kinase* or sphingosine kinase should be understood as molecules exhibiting any one or more of the functional activities of *sphingosine kinase* or sphingosine kinase and may be derived from any source such as being chemically synthesized or identified via screening processes such as natural product screening.

[0029] The derivatives of sphingosine kinase include fragments having particular epitopes or parts of the entire sphingosine kinase protein fused to peptides, polypeptides or other proteinaceous or non-proteinaceous molecules.

[0030] Analogues of sphingosine kinase contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecules or their analogues.

[0031] Derivatives of nucleic acid sequences may similarly be derived from single or multiple nucleotide substitutions, deletions and/or additions including fusion with other nucleic acid molecules. The derivatives of the nucleic acid molecules of the present invention include oligonucleotides, PCR primers, antisense molecules, molecules suitable for use in

cosuppression and fusion of nucleic acid molecules. Derivatives of nucleic acid sequences also include degenerate variants.

[0032] Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH₄; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride, and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH₄.

[0033] The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

[0034] The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

[0035] Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

[0036] Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

[0037] Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carboethoxylation with diethylpyrocarbonate.

[0038] Examples of incorporating unnatural amino acids and derivatives during protein synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminoheptanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid contemplated herein is shown in Table 2.

TABLE 2

Non-conventional amino acid	Code	Non-conventional amino acid	Code
α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
aminocyclopropane-carboxylate	Cpro	L-N-methylasparagine	Nmasn
aminoisobutyric acid	Aib	L-N-methylaspartic acid	Nmasp
aminonorbomyl-carboxylate	Norb	L-N-methylcysteine	Nmcys
cyclohexylalanine		L-N-methylglutamine	Nmgln
cyclopentylalanine	Cpen	L-N-methylglutamic acid	Nmglu
D-alanine	Dal	Chexa L-N-methylhistidine	Nmhis
D-arginine	Darg	L-N-methylisoleucine	Nmile
D-aspartic acid	Das	L-N-methylleucine	Nmleu
D-cysteine	Dcys	L-N-methyllysine	Nmlys
D-glutamine	Dgln	L-N-methylmethionine	Nmmet
D-glutamic acid	Dglu	L-N-methylnorleucine	Nmnle
D-histidine	Dhis	L-N-methylnorvaline	Nmnva
D-isoleucine	Dile	L-N-methylornithine	Nmorn
D-leucine	Dleu	L-N-methylphenylalanine	Nmphe
D-lysine	Dlys	L-N-methylproline	Nmpro
D-methionine	Dmet	L-N-methylserine	Nmser
D-ornithine	Dom	L-N-methylthreonine	Nmthr
D-phenylalanine	Dphe	L-N-methyltryptophan	Nmtrp
D-proline	Dpro	L-N-methyltyrosine	Nmtyr
D-serine	Dser	L-N-methylvaline	Nmval
D-threonine	Dthr	L-N-methylethylglycine	Nmetg
D-tryptophan	Dtrp	L-N-methyl-t-butylglycine	Nmtbug
		L-norleucine	Nle
		L-norvaline	Nva

(continued)

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
5	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
10	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
15	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylomithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
20	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
25	D- α -methyltyrosine	Dmtyr	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
30	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
35	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolyethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
40	D-N-methylomithine	Dnmom	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
45	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
50	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
55	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe

(continued)

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
5	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
10	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhph
	N-(N-(2,2-diphenylethyl) carbonylmethyl)glycine	Nnbhm	N-(N-(3,3-diphenylpropyl) carbonylmethyl)glycine	Nnbhe
15	1-carboxy-1-(2,2-diphenyl-Nmbc ethylamino)cyclopropane			

[0039] Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH₂)_n spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety.

[0040] The nucleic acid molecule of the present invention is preferably in isolated form or ligated to a vector, such as an expression vector. By "isolated" is meant a nucleic acid molecule having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject nucleic acid molecule, preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject nucleic acid molecule relative to other components as determined by molecular weight, encoding activity, nucleotide sequence, base composition or other convenient means. The nucleic acid molecule of the present invention may also be considered, in a preferred embodiment, to be biologically pure.

[0041] The term "protein" should be understood to encompass peptides, polypeptides and proteins. The protein may be glycosylated or unglycosylated and/or may contain a range of other molecules fused, linked, bound or otherwise associated to the protein such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins. Reference hereinafter to a "protein" includes a protein comprising a sequence of amino acids as well as a protein associated with other molecules such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins.

[0042] In a particularly preferred embodiment, the nucleotide sequence corresponding to *sphingosine kinase* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>1 or a derivative or analogue thereof including a nucleotide sequence having similarity to <400>1.

[0043] A derivative of a nucleic acid molecule of the present invention also includes a nucleic acid molecule capable of hybridising to a nucleotide sequence as set forth in <400>1 under low stringency conditions. Preferably, low stringency is at 42°C.

[0044] The nucleic acid molecule may be ligated to an expression vector capable of expression in a prokaryotic cell (e.g. *E. coli*) or a eukaryotic cell (e.g. yeast cells, fungal cells, insect cells, mammalian cells or plant cells). The nucleic acid molecule may be ligated or fused or otherwise associated with a nucleic acid molecule encoding another entity such as, for example, a signal peptide. It may also comprise additional nucleotide sequence information fused, linked or otherwise associated with it either at the 3' or 5' terminal portions or at both the 3' and 5' terminal portions. The nucleic acid molecule may also be part of a vector, such as an expression vector. The latter embodiment facilitates production of recombinant forms of sphingosine kinase which forms are encompassed by the present invention.

[0045] The present invention extends to the expression product of the nucleic acid molecules as hereinbefore defined.

[0046] The expression product is sphingosine kinase having an amino acid sequence set forth in <400>2 or is a derivative, analogue or chemical equivalent or mimetic thereof as defined above or is a derivative or mimetic having an amino acid sequence of at least about 45% similarity to at least 10 contiguous amino acids in the amino acid sequence as set forth in <400>2 or a derivative or mimetic thereof.

[0047] Another aspect of the present invention is directed to an isolated protein selected from the list consisting of:

- (i) A novel sphingosine kinase protein or a derivative, analogue, chemical equivalent or mimetic thereof.
- (ii) A human sphingosine kinase protein or a derivative, analogue, chemical equivalent or mimetic thereof.

(iii) A protein having an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2 or a derivative analogue, chemical equivalent or mimetic of said protein.

(iv) A protein encoded by a nucleotide sequence substantially as set forth in <400>1 or a derivative or analogue thereof or a sequence encoding an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2 or a derivative, analogue, chemical equivalent or mimetic of said protein.

(v) A protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in <400>1 or a derivative or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2.

(vi) A protein as defined in paragraphs (i) or (ii) or (iii) or (iv) or (v) in a homodimeric form.

(vii) A protein as defined in paragraphs (i) or (ii) or (iii) or (iv) or (v) in a heterodimeric form.

[0048] The protein of the present invention is preferably in isolated form. By "isolated" is meant a protein having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject protein, preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject protein relative to other components as determined by molecular weight, amino acid sequence or other convenient means. The protein of the present invention may also be considered, in a preferred embodiment, to be biologically pure.

[0049] The sphingosine kinase of the present invention may be in multimeric form meaning that two or more molecules are associated together. Where the same sphingosine kinase molecules are associated together, the complex is a homomultimer. An example of a homomultimer is a homodimer. Where at least one sphingosine kinase is associated with at least one non-sphingosine kinase molecule, then the complex is a heteromultimer such as a heterodimer.

[0050] The ability to produce recombinant sphingosine kinase permits the large scale production of sphingosine kinase for commercial use. The sphingosine kinase may need to be produced as part of a large peptide, polypeptide or protein which may be used as is or may first need to be processed in order to remove the extraneous proteinaceous sequences. Such processing includes digestion with proteases, peptidases and amidases or a range of chemical, electrochemical, sonic or mechanical disruption techniques.

[0051] Notwithstanding that the present invention encompasses recombinant proteins, chemical synthetic techniques are also preferred in synthesis of sphingosine kinase.

[0052] Sphingosine kinase according to the present invention is conveniently synthesised based on molecules isolated from the human. Isolation of the human molecules may be accomplished by any suitable means such as by chromatographic separation, for example using CM-cellulose ion exchange chromatography followed by Sephadex (e.g. G-50 column) filtration. Many other techniques are available including HPLC, PAGE amongst others.

[0053] Sphingosine kinase may be synthesised by solid phase synthesis using F-moc chemistry as described by Carpino *et al.* (1991). Sphingosine kinase and fragments thereof may also be synthesised by alternative chemistries including, but not limited to, t-Boc-chemistry as described in Stewart *et al.* (1985) or by classical methods of liquid phase peptide synthesis.

[0054] Without limiting the theory or mode of action of the present invention, sphingosine kinase is a key regulatory enzyme in the activity of the sphingosine kinase signalling pathway. By "sphingosine kinase signalling pathway" is meant a signalling pathway which utilises one or both of sphingosine kinase and/or sphingosine-1-phosphate. It is thought that a sphingosine kinase signalling pathway cascade which results in adhesion molecule expression may take the form of:

(i) the generation of ceramide from sphingomyelin via *S.Mase* activity, said ceramide being converted to sphingosine;

(ii) sphingosine-1-phosphate (referred to hereinafter as "Sph-1-P") generation by stimulation of sphingosine kinase; and

(iii) the activation of MEK/ERK and nuclear translocation of NF- κ B downstream from Sph-1-P generation.

[0055] The sphingosine kinase signalling pathway is known to regulate cellular activities such as those which lead to inflammation, apoptosis and cell proliferation. For example, upregulation of the production of inflammatory mediators such as cytokines, chemokines, eNOS and upregulation of adhesion molecule expression. Said upregulation may be

induced by a number of stimuli including, for example, inflammatory cytokines such as tumour necrosis factor- α (TNF- α) and interleukin-1 (IL-1), endotoxin, oxidised or modified lipids, radiation or tissue injury.

[0056] The cloning and sequencing of this gene and its expression product now provides additional molecules for use in the prophylactic and therapeutic treatment of diseases characterised by unwanted cellular activity, which activity is either directly or indirectly modulated via the activity of the sphingosine kinase signalling pathway. Examples of diseases involving unwanted sphingosine kinase regulated cellular activity include rheumatoid arthritis, asthma, atherosclerosis, meningitis, multiple sclerosis and septic shock. Accordingly, the present invention contemplates therapeutic and prophylactic uses of sphingosine kinase amino acid and nucleic acid molecules, in addition to sphingosine kinase agonistic and antagonistic agents, for the regulation of cellular functional activity, such as for example, regulation of inflammation.

[0057] The present invention contemplates, therefore, a method for modulating expression of *sphingosine kinase* in a subject, said method comprising contacting the *sphingosine kinase* gene with an effective amount of an agent for a time and under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of *sphingosine kinase*. For example, *sphingosine kinase* antisense sequences such as oligonucleotides may be introduced into a cell to down-regulate one or more specific functional activities of that cell. Conversely, a nucleic acid molecule encoding sphingosine kinase or a derivative thereof may be introduced to up-regulate one or more specific functional activities of any cell not expressing the endogenous *sphingosine kinase* gene.

[0058] Another aspect of the present invention contemplates a method of modulating activity of sphingosine kinase in a mammal, said method comprising administering to said mammal a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease sphingosine kinase activity.

[0059] Modulation of said activity by the administration of an agent to a mammal can be achieved by one of several techniques, including but in no way limited to introducing into said mammal a proteinaceous or non-proteinaceous molecule which:

(i) modulates expression of *sphingosine kinase*;

(ii) functions as an antagonist of sphingosine kinase;

(iii) functions as an agonist of sphingosine kinase.

[0060] Said proteinaceous molecule may be derived from natural or recombinant sources including fusion proteins or following, for example, natural product screening. Said non-proteinaceous molecule may be, for example, a nucleic acid molecule or may be derived from natural sources, such as for example natural product screening or may be chemically synthesised. The present invention contemplates chemical analogs of sphingosine kinase or small molecules capable of acting as agonists or antagonists of sphingosine kinase.

Chemical agonists may not necessarily be derived from sphingosine kinase but may share certain conformational similarities. Alternatively, chemical agonists may be specifically designed to mimic certain physiochemical properties of sphingosine kinase. Antagonists may be any compound capable of blocking, inhibiting or otherwise preventing sphingosine kinase from carrying out its normal biological functions. Antagonists include monoclonal antibodies specific for sphingosine kinase, or parts of sphingosine kinase, and antisense nucleic acids which prevent transcription or translation of *sphingosine kinase* genes or mRNA in mammalian cells. Modulation of *sphingosine kinase* expression may also be achieved utilising antigens, RNA, ribosomes, DNazymes, RNA aptamers or antibodies.

[0061] Said proteinaceous or non-proteinaceous molecule may act either directly or indirectly to modulate the expression of *sphingosine kinase* or the activity of sphingosine kinase. Said molecule acts directly if it associates with *sphingosine kinase* or sphingosine kinase to modulate the expression or activity of *sphingosine kinase* or sphingosine kinase. Said molecule acts indirectly if it associates with a molecule other than *sphingosine kinase* or sphingosine kinase which other molecule either directly or indirectly modulates the expression or activity of *sphingosine kinase* or sphingosine kinase. Accordingly, the method of the present invention encompasses the regulation of *sphingosine kinase* or sphingosine kinase expression or activity via the induction of a cascade of regulatory steps which lead to the regulation of *sphingosine kinase* or Sphingosine kinase expression or activity.

[0062] Another aspect of the present invention contemplates a method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of a nucleotide sequence encoding sphingosine kinase or sufficient to modulate the activity of sphingosine kinase.

[0063] Yet another aspect of the present invention contemplates a method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of sphingosine kinase or *sphingosine kinase*.

[0064] The sphingosine kinase, *sphingosine kinase* or agent used may also be linked to a targeting means such as a monoclonal antibody, which provides specific delivery of the sphingosine kinase, *sphingosine kinase* or agent to the

target cells.

[0065] In a preferred embodiment of the present invention, the sphingosine kinase, *sphingosine kinase* or agent used in the method is linked to an antibody specific for said target cells to enable specific delivery to these cells.

[0066] Reference to "modulating cellular functional activity" is a reference to up-regulating, down-regulating or otherwise altering any one or more of the activities which a cell is capable of performing such as, but not limited to, one or more of chemokine production, cytokine production, nitric oxide synthetase, adhesion molecule expression and production of other inflammatory modulators.

[0067] Administration of the sphingosine kinase, *sphingosine kinase* or agent, in the form of a pharmaceutical composition, may be performed by any convenient means. Sphingosine kinase, *sphingosine kinase* or agent of the pharmaceutical composition are contemplated to exhibit therapeutic activity when administered in an amount which depends on the particular case. The variation depends, for example, on the human or animal and the sphingosine kinase, *sphingosine kinase* or agent chosen. A broad range of doses may be applicable. Considering a patient, for example, from about 0.1 mg to about 1 mg of sphingosine kinase or agent may be administered per kilogram of body weight per day. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, weekly, monthly or other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the situation. The sphingosine kinase or agent may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intranasal, intraperitoneal, intramuscular, subcutaneous, intradermal or suppository routes or implanting (e.g. using slow release molecules). With particular reference to use of sphingosine kinase or agent, these peptides may be administered in the form of pharmaceutically acceptable nontoxic salts, such as acid addition salts or metal complexes, e.g. with zinc, iron or the like (which are considered as salts for purposes of this application). Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulphate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate and the like. If the active ingredient is to be administered in tablet form, the tablet may contain a binder such as tragacanth, corn starch or gelatin; a disintegrating agent, such as alginic acid; and a lubricant, such as magnesium stearate.

[0068] A further aspect of the present invention relates to the use of the invention in relation to mammalian disease conditions. For example, the present invention is particularly useful, but in no way limited to, use in inflammatory diseases.

[0069] Accordingly, another aspect of the present invention relates to a method of treating a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *sphingosine kinase* or sufficient to modulate the activity of sphingosine kinase wherein said modulation results in modulation of cellular functional activity.

[0070] In another aspect the present invention relates to a method of treating a mammal said method comprising administering to said mammal an effective amount of sphingosine kinase or *sphingosine kinase* for a time and under conditions sufficient to modulate cellular functional activity.

[0071] Yet another aspect of the present invention relates to the use of an agent capable of modulating the expression of *sphingosine kinase* or modulating the activity of sphingosine kinase in the manufacture of a medicament for the modulation of cellular functional activity.

[0072] A further aspect of the present invention relates to the use of sphingosine kinase or *sphingosine kinase* in the manufacture of a medicament for the modulation of cellular functional activity.

[0073] Still yet another aspect of the present invention relates to agents for use in modulating *sphingosine kinase* expression or sphingosine kinase activity wherein said modulation results in modulation of cellular functional activity.

[0074] Another aspect of the present invention relates to sphingosine kinase or *sphingosine kinase* for use in modulating cellular functional activity.

[0075] In a related aspect of the present invention, the mammal undergoing treatment may be a human or an animal in need of therapeutic or prophylactic treatment.

[0076] In yet another further aspect the present invention contemplates a pharmaceutical composition comprising *sphingosine kinase*, sphingosine kinase or an agent capable of modulating *sphingosine kinase* expression or sphingosine kinase activity together with one or more pharmaceutically acceptable carriers and/or diluents. *Sphingosine kinase*, sphingosine kinase or said agent are referred to as the active ingredients.

[0077] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars

or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0078] Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

[0079] When *sphingosine kinase*, sphingosine kinase and sphingosine kinase modulators are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 μ g and 2000 mg of active compound.

[0080] The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

[0081] Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

[0082] It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired.

[0083] The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5 μ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 μ g to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

[0084] The pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable of expressing *sphingosine kinase*, modulating *sphingosine kinase* expression or sphingosine kinase activity. The vector may, for example, be a viral vector.

[0085] *Sphingosine kinase* can also be utilised to create gene knockout models in either cells or non-human animals, which knocked out gene is the sphingosine kinase gene expressed by said cells or animals. Accordingly in another aspect the present invention should be understood to extend to methods of creating sphingosine kinase gene cell or non-human animal knockout models wherein sphingosine kinase has been utilised to facilitate knocking out of the endogenous sphingosine kinase gene of said cell or animal, and to the knockout models produced therefrom.

[0086] Still another aspect of the present invention is directed to antibodies to sphingosine kinase including catalytic

antibodies. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to sphingosine kinase or may be specifically raised to sphingosine kinase. In the case of the latter, sphingosine kinase may first need to be associated with a carrier molecule. The antibodies and/or recombinant sphingosine kinase of the present invention are particularly useful as therapeutic or diagnostic agents.

[0087] Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore, the present invention extends to recombinant and synthetic antibodies and to antibody hybrids. A "synthetic antibody" is considered herein to include fragments and hybrids of antibodies. The antibodies of this aspect of the present invention are particularly useful for immunotherapy and may also be used as a diagnostic tool, for example, for monitoring the program of a therapeutic regime.

[0088] For example, sphingosine kinase can be used to screen for naturally occurring antibodies to sphingosine kinase. These may occur, for example in some inflammatory disorders.

[0089] For example, specific antibodies can be used to screen for sphingosine kinase proteins. The latter would be important, for example, as a means for screening for levels of sphingosine kinase in a cell extract or other biological fluid or purifying sphingosine kinase made by recombinant means from culture supernatant fluid. Techniques for the assays contemplated herein are known in the art and include, for example, sandwich assays, ELISA and flow cytometry.

[0090] It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any region of sphingosine kinase.

[0091] Both polyclonal and monoclonal antibodies are obtainable by immunization with the protein or peptide derivatives and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of sphingosine kinase, or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

[0092] The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art. (See, for example Douillard and Hoffman, Basic Facts about Hybridomas, in Compendium of Immunology Vol II, ed. by Schwartz, 1981; Kohler and Milstein, Nature 256: 495-499, 1975; European Journal of Immunology 6: 511-519, 1976).

[0093] In another aspect of the present invention, the molecules of the present invention are also useful as screening targets for use in applications such as the diagnosis of disorders which are regulated by sphingosine kinase.

[0094] Yet another aspect of the present invention contemplates a method for detecting sphingosine kinase or *sphingosine kinase* mRNA in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for sphingosine kinase or *sphingosine kinase* mRNA or its derivatives or homologs for a time and under conditions sufficient for an antibody-sphingosine kinase or antibody-sphingosine kinase mRNA complex to form, and then detecting said complex.

[0095] The presence of sphingosine kinase may be determined in a number of ways such as by Western blotting, ELISA or flow cytometry procedures. Sphingosine kinase mRNA may be detected, for example, by *in situ* hybridization or Northern blotting. These, of-course, include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

[0096] Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is one which might contain sphingosine kinase including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological

sample comprising biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.

[0097] In the typical forward sandwich assay, a first antibody having specificity for the sphingosine kinase or antigenic parts thereof, is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes) and under suitable conditions (e.g. 25°C) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.

[0098] An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

[0099] By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

[0100] In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. "Reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

[0101] Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

[0102] The present invention also contemplates genetic assays such as involving PCR analysis to detect *sphingosine kinase* or its derivatives.

[0103] Further features of the present invention are more fully described in the following nonlimiting examples.

EXAMPLE 1

PURIFICATION AND CLONING OF HUMAN SPHINGOSINE KINASE - EXPERIMENTAL PROCEDURES

Materials

[0104] D-*erythro*-Sphingosine, D-*erythro*-dihydrosphingosine, DL-*threo*-dihydrosphingosine, N,N-dimethylsphingosine, N-acetylsphingosine (C₂-ceramide), S1P and Fumisin B1 were purchased from Biomol Research Laboratories Inc. (Plymouth Meeting, PA).

Phytosphingosine, L- α -phosphatidic acid, L- α -phosphatidylinositol, L- α -phosphatidylserine, L- α -phosphatidylcholine,

L- α -phosphatidylethanolamine, 1,2. dioctanoyl-sn-glycerol, 1,2-dioleoyl-sn-glycerol, ATP, calmodulin, glutathione and bovine serum albumin (BSA) were from Sigma. *N,N,N*-trimethylsphingosine and ADP were purchased from Calbiochem (Band Soden, Germany), [γ - 32 P]ATP from Geneworks (Adelaide, South Australia), TNF α from R&D Systems Inc. (Minneapolis, MN), and isopropyl- β -D-thiogalactoside (IPTG) from Promega (Madison, WI). Prepacked Mono-Q, Superose 75 and HiTrap-Q columns, Q Sepharose fast flow, calmodulin Sepharose 4B, glutathione Sepharose 4B, thrombin and gel filtration molecular mass protein standards were from Amersham Pharmacia Biotech. SDS-PAGE molecular mass protein standards, silver stain plus kit, Coomassie Brilliant Blue R250 and Coomassie protein reagent were from Bio-Rad. Centricon concentrators were purchased from Amicon Inc. (Beverly, MA) and BCA protein reagent was from Pierce Chemical Company (Rockford, IL).

Sphingosine kinase enzyme assay

[0105] Sphingosine kinase activity was routinely determined using D-*erythro*-sphingosine and [γ - 32 P]ATP as substrates, essentially as previously described (Olivera *et al.*, 1998) with some modifications. Briefly, assays were performed by incubating samples at 37°C for 30 min with sphingosine (100 μ M stock dissolved in 5% Triton X-100) and [γ - 32 P]ATP (1 mM; 10 μ Ci/ml) in assay buffer containing 100 mM Tris/HCl I (pH 7.4), 10 mM MgCl₂, 10% (v/v) glycerol, 1 mM dithiothreitol, 1 mM EGTA, 1 mM Na₃VO₄, 15mM NaF, 0.5 mM 4-deoxypyridoxine in a total volume of 100 μ l. Reactions were terminated and sphingosine-1-phosphate extracted by the addition of 700 μ l of chloroform/methanol/HCl (100:200:1, v/v), followed by vigorous mixing, addition of 200 μ l of chloroform and 200 μ l of 2 M KCl, and phase separation by centrifugation. The labeled S1P in the organic phase was isolated by TLC on Silica Gel 60 with 1-butanol/ethanol/acetic acid/water (8:2:1:2, v/v) and quantitated by phosphorimager (Molecular Dynamics, Sunnyvale, CA). One unit (U) of activity is defined as 1 pmol of S1P formed per minute.

Purification of sphingosine kinase from human placenta

[0106] Sphingosine kinase was purified from 1240 g of human placenta (4 placentas), with all steps performed at 4°C. The placentas were diced, washed in buffer A (25 mM Tris/HCl buffer, pH 7.4 containing 10% (v/v) glycerol, 0.05% Triton X-100 and 1 mM dithiothreitol), transferred to 1.5 L of fresh buffer A containing a protease inhibitor cocktail (Complete™; Boehringer Mannheim) (buffer B), and minced in a Waring blender. The resultant homogenate was stored on ice for 30 min to enhance enzyme extraction, and the soluble fraction of the homogenate then isolated by centrifugation at 17 000 g for 60 min. This preparation was then fractionated by (NH₄)₂SO₄ precipitation by the addition of solid (NH₄)₂SO₄ at pH 7.4 and collection of the precipitated proteins by centrifugation (17 000 g, 30 min). The 25-35%-saturated (NH₄)₂SO₄ fraction was then redissolved in a buffer B, desalted by extensive dialysis against this same buffer, and centrifuged (17 000 g, 30 min) to remove insoluble material. All subsequent chromatographic steps were performed using a FPLC system (Pharmacia Biotech) at 4°C.

[0107] The dialysed (NH₄)₂SO₄ fraction was applied to a Q-Sepharose fast flow column (50 mm diameter, 250 ml bed volume) pre-equilibrated with buffer A at a flow rate of 7 ml/min. Sphingosine kinase activity was eluted with a NaCl gradient of 0 to 1M in buffer A and collected in 10 ml fractions. Fractions containing highest SK1 activity were then combined, and CaCl₂ and NaCl added to give final concentrations of 4 mM and 250 mM, respectively. This pooled extract was then applied to a calmodulin-Sepharose 4B column (16 mm diameter, 10 ml bed volume), pre-equilibrated with buffer A containing 2 mM CaCl₂, at a flow rate of 1 ml/min. The column was then washed with several column volumes of equilibration buffer, followed by buffer A containing 4 mM EGTA, and then SKI eluted with buffer A containing 4 mM EGTA and 1 M NaCl. The fractions-containing highest sphingosine kinase activity were pooled, desalted on a Sephadex G-25 column, and applied at a flow rate of 1 ml/min to a Mono-Q column (5 mm diameter, 1 ml bed volume) pre-equilibrated with buffer A. Sphingosine kinase activity was eluted with a NaCl gradient to 0 to 1M in buffer A. NaCl (to 500 mM) was immediately added to the fractions (1 ml) collected to stabilise enzyme activity. The Mono-Q fractions containing highest sphingosine kinase activity were combined and desalted on a Sephadex G-25 column. ATP and MgCl₂ were then added to the pooled fractions to a final concentrations of 1 mM and 5 mM, respectively, before reapplication at a flow rate of 1 ml/min to the Mono-Q column pre-equilibrated with buffer A containing 1 mM ATP and 5 mM MgCl₂. Sphingosine kinase activity was eluted with a NaCl gradient of 0 to 1M in the equilibration buffer. Again, NaCl (to 500 mM) was immediately added to the fractions (1 ml) collected to stabilise enzyme activity. The ATP-Mono-Q fractions containing highest sphingosine kinase activity were pooled and concentrated 10-fold to a final volume of 200 μ l in a Centricon-10 concentrator and applied at a flow rate of 0.4 ml/min to a Superdex 75 column (10 mm diameter, 20 ml bed volume) pre-equilibrated with buffer A containing 500 mM NaCl. Sphingosine kinase activity was eluted with the same buffer and 0.4 ml fractions collected. The molecular mass of the enzyme was estimated from this column by comparison to the elution volumes of ribonuclease A, chymotrypsinogen A, ovalbumin and BSA.

Cloning of human sphingosine kinase

[0108] The human sphingosine kinase (hSK) was amplified from a HUVEC λ Zap cDNA library using PCR primers derived from human EST sequences (GenBank™ accession numbers D31133, W63556, AA026479, AA232791, AA081152, A1769914 and A1769914) aligned to the murine sphingosine kinases (Olivera *et al.*, 1998). These primers, spanning a central *Sac*II site (P1, 5'-CGGAATTCCCAGTCGGCCGCGTA-3' [<400>3] and P2, 5'-TAGAATTCTAC-CGCGGCCGACTGGCT-3' [<400>4]), were used in combination with T3 and T7 primers to generate two overlapping PCR products of 669 bp and 550 bp that represented the 5' and 3' ends of hSK, respectively. These two PCR products were then separately cloned into pGEM4Z. A 584 bp *Sac*II fragment from the 5' hSK PCR clone was then sub-cloned in the correct orientation into the *Sac*II site of the 3' hSK PCR clone, to generate a 1130 bp partial hSK cDNA clone. A full length clone encoding hSK was then generated by sub-cloning a 120 bp *Eco*RI/*Stu*I fragment from the 669 bp 5' hSK clone into this pGEM4Z-1130 bp clone digested with *Eco*RI/*Stu*I. Sequencing the cDNA clone in both directions verified the integrity of the hSK cDNA sequence.

[0109] For mammalian cell expression the hSK cDNA was FLAG epitope tagged at the 3'-end by PFU polymerase PCR with oligonucleotide primers T7 and 5'-TAGAATTCACCTTGTCATCGTCGTCCTTGTAGTCTAAGGGCTCTTCT-GGCGGT-3' [<400>5]. This FLAG-tagged hSK cDNA was then cloned into pCDNA3 by digestion with *Eco*RI. The orientation was determined by restriction analysis and sequencing verified the integrity of the hSK-FLAG cDNA sequence. For bacterial expression, the full length hSK cDNA was sub-cloned into pGEX4T2. The pGEM4Z-hSK clone was digested with *Bam*HI and blunted with 3U PFU polymerase in 1 x PFU buffer, 50 μ M dNTP's at 72°C for 30 minutes. The 1163 bp hSK cDNA was gel purified following digestion with *Sa*II and the blunt/*Sa*II fragment was then ligated to pGEX4T2 *Sma*I/*Xho*I.

Sphingosine kinase amino acid sequence analysis

[0110] The human sphingosine kinase amino acid sequence was searched against non-redundant amino acid and nucleotide sequence databases at the Australian National Genome Information Service using the blastp and tblastn algorithms (Altschul *et al.*, 1990).

Cell culture

[0111] Human umbilical vein endothelial cells (HUVEC) were isolated as previously described (Wall *et al.*, 1978) and cultured on gelatin-coated culture flasks in medium M199 with Earle's salts supplemented with 20% fetal calf serum, 25 μ g/ml endothelial growth supplement (Collaborative Research) and 25 μ g/ml heparin. The cells were passaged three times and grown to 80% confluency before treatment and harvesting. Human embryonic kidney cells (HEK293, ATCC CRL-1573) cells were cultured on Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 2 mM glutamine, 0.2% (w/v) sodium bicarbonate, penicillin (1.2 mg/ml), and gentamycin (1.6 mg/ml). HEK293 cells were transiently transfected using the calcium phosphate precipitation method (Graham & van der Eb, 1973). Treatment of HUVEC and HEK293 cells with TNF α (1 ng/ml) was performed as previously described (Xia *et al.*, 1998).

EXAMPLE 2

EXPRESSION AND ISOLATION OF RECOMBINANT HUMAN SPHINGOSINE KINASE FROM *E. COLI* - EXPERIMENTAL PROCEDURE

[0112] The full length SPHK cDNA cloned into pGEX4T2 was transformed into *E. coli* BL21. Overnight cultures (100 ml) of transformed isolates were grown with shaking (200 rpm) at 30°C in Superbroth (20 g/L glucose, 35 g/L tryptone, 20 g/L yeast extract, 5 g/L NaCl, pH 7.5) medium containing ampicillin (100 mg/L). The cultures were diluted 1:20 in fresh medium and grown at 30°C with shaking to an OD₆₀₀ of 0.6-0.7. Expression of the glutathione-s-transferase (GST)-coupled sphingosine kinase (GST-SK) was then induced by addition of 0.1 mM isopropyl- β -D-thiogalactoside and further incubation of the cultures at 30°C for 3 h. After this time the bacterial cells were then harvested by centrifugation at 6,000 g for 20 min at 4°C and resuspended in 20 ml of buffer B containing 250 mM NaCl, the cells were then lysed with lysozyme at a final concentration of 0.3 mg/ml for 15 min at 25°C followed by sonication, consisting of three cycles of 20s ultrasonic pulses followed by one minute cooling. The lysate was then clarified by centrifugation at 50,000 g for 45 min at 4°C, followed by filtrating through 0.22 μ m filters. To be filtered supernatant was then incubated with 0.2 volumes of 50% (w/v) glutathione-Sepharose 4B (Pharmacia) that was washed and pro-equilibrated with buffer B, for 60 min at 4°C with constant mixing. After this time the mixture was poured into a glass chromatography column (10 mm diam.) and the beads (with bound GST-SK) washed with 10 column volumes of buffer B at 4°C. The GST-SK was then eluted from the column in 10 ml of buffer B containing 10 mM reduced glutathione. Cleavage of the GST away from

sphingosine kinase was then performed by incubation with 20 µg (30 N.I.H. units) thrombin (Pharmacia) for 3h at 25°C. The released sphingosine kinase was then purified by application of the cleavage mix to a calmodulin-Sepharose column and then a Mono-Q anion exchange column for the purification of the sphingosine kinase from human placenta. These columns resulted in purification of the recombinant sphingosine kinase to homogeneity.

EXAMPLE 3

CHARACTERISATION OF SPHINGOSINE KINASES - EXPERIMENTAL PROCEDURES

[0113] The effect of pH on the activity of the isolated sphingosine kinases was determined over the pH range 4.0 to 11.0 in 50 mM buffers (sodium acetate, pH 4.0-5.0; Mes, pH 6.0-7.0; Hepes, pH 7.0-8.2; Tris/HCl, pH 8.2-10.0; Caps, pH 10.0-11.0) at 37°C. pH stability was determined by assaying the residual activity after pre-incubation of the enzymes in the same buffers for 5h at 4°C. Similarly, thermal stabilities were determined by assaying the residual activity after pre-incubation of the enzymes at various temperatures (4-80°C) for 30 min at pH 7.4 (50mM Tris/HCl containing 10% glycerol, 0.5 M NaCl and 0.05% Triton X-100). Substrate kinetics were analysed using Michaelis-Menten kinetics with a weighted non-linear regression program (Easterby, 1996). Since sphingosine and its analogues were added to the enzyme assays in mixed micelles with Triton X-100, where they exhibit surface dilution kinetics (Buehrer and Bell, 1992), all K_m and K_i values obtained for these molecules were expressed as mol % of Triton X-100, rather than as bulk solution concentrations. For assays to determine the effect of calcium/calmodulin on sphingosine kinase activity, calcium and calmodulin were added to the standard assay mixtures containing 20 nM of isolated sphingosine kinase at final concentrations of 4 mM and 0.6 µM, respectively.

EXAMPLE 4

OTHER ANALYTICAL METHODS

[0114] Protein was determined using either the Coomassie Brilliant Blue (Bradford *et al.*, 1976) or Bicinchoninic acid (Smith *et al.*, 1985) reagents using BSA as standard. In some cases protein estimations were performed after concentration and removal of detergent by precipitation (Wessel and Flügge, 1984) to increase the sensitivity and accuracy of the determinations. SDS-PAGE was performed according to the method of Laemmli (1970) using 12% acrylamide gels. Protein bands on gels were visualised with either Coomassie Brilliant Blue R250 or silver staining. Molecular mass was estimated by comparison to the electrophoretic mobility of myosin, β-galactosidase, BSA, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor, lysozyme and aprotinin.

EXAMPLE 5

PURIFICATION OF HUMAN SPHINGOSINE KINASE - RESULTS

[0115] Just over half of the total sphingosine kinase activity in human placenta was present in the cytosol after tissue homogenisation (Table 3). The purification of sphingosine kinase from human placenta is summarised in Table 4. The soluble fraction from the homogenate of four human placentae was initially subjected to ammonium sulphate precipitation. This resulted in a remarkably good purification of sphingosine kinase (33-fold), which precipitated in the 25-35% saturated ammonium sulphate fraction. For anion exchange chromatography the ammonium sulphate fraction was rapidly desalted through the use of Sephadex G25 column and the desalted fraction loaded immediately onto a Q Sepharose FF column. The speed of this desalting step appeared critical since the sphingosine kinase activity appeared very unstable at NaCl concentrations below about 0.2 M, meaning slower desalting steps, such as dialysis, resulted in substantial losses of enzyme activity. Application of a NaCl gradient of 0 to 1 M to the Q Sepharose FF column resulted in two peaks of sphingosine kinase activity, eluting at approximately 0.15 M and 0.6 M NaCl, and designated SK1 and SK2, respectively (Fig. 2). For this study SK1 was selected for further purification due to its greater abundance and stability; SK2 activity appeared very unstable and, unlike SK1, could not be stabilised by the addition of 0.5M NaCl, 10% glycerol and 0.05% Triton X-100. SK1 was also chosen since it appeared to be the isoform present in HUVEC, as discussed later.

[0116] Fractions from Q Sepharose FF column containing SK1 were then affinity purified by application to a calmodulin-Sepharose 4B column in the presence of 4mM CaCl_2 , and elution of SK1 performed with EGTA and NaCl, resulting in further substantial purification (38-fold) and high enzyme yields. SK1 could not be eluted from the calmodulin Sepharose 4B column with EGTA alone; indicating an unusual association of the enzyme with this affinity matrix. The active fractions that eluted from the calmodulin Sepharose 4B column were then desalted and applied to two subsequent steps of analytical anion exchange chromatography on a Mono Q column, with the second step performed in the presence of 1 mM ATP and 5mM MgCl_2 (Fig. 3). The active fractions resulting from these anion exchange steps were then applied

to gel filtration chromatography with a Superdex 75 column as a final purification step. SK1 eluted from this column as a single peak with a molecule mass corresponding to 44 kDa. Analysis of the active fraction from this final column by SDS-PAGE with silver staining (Fig. 4) revealed a single band of molecular mass 45kDa, indicating a homogenous protein that has been purified over a million-fold from the original placenta extract with remarkably good yield of 7% of the original sphingosine kinase activity (Table 4). This is the first sphingosine kinase to be purified to homogeneity from a human source.

EXAMPLE 6

SPHINGOSINE KINASE ISOFORMS IN HUVEC - RESULTS

[0117] Since two sphingosine kinase activities were identified in human placenta (Fig 2) we examined the multiplicity of this enzyme activity in HUVEC by the use of preparative anion exchange columns. In contrast to other human tissues and cells, application of HUVEC extracts to these columns resulted in the appearance of only a single sphingosine kinase peak that eluted at the same point as the human placenta SK1 (Fig. 5). Similarly, only a single sphingosine kinase peak eluted after application of HUVEC extracts in which sphingosine kinase activity had been stimulated by 10 min treatment of HUVEC with $\text{TNF}\alpha$ (Xia *et al.*, 1999). These results would indicate that SK1, the human placenta sphingosine kinase isolated in this study, is probably the main isoform found in HUVEC, and that $\text{TNF}\alpha$ treatment results in an increase in the activity of this enzyme, rather than the activation of another, otherwise latent, isoform.

EXAMPLE 7

CLONING OF HUMAN SPHINGOSINE KINASE AND TRANSIENT EXPRESSION IN HEK293 CELLS - RESULTS

[0118] A human sphingosine kinase cDNA was generated from a HUVEC λ Zap library using primers designed from human ESTs aligned with the published murine sphingosine kinase sequence (Kohama *et al.*, 1998). The cloning strategy is shown in Figure 6 (prov). The cDNA has an apparent open reading frame coding for 384 amino acids (Fig. 7), it should be noted that the sequence lacked a recognisable Kozak consensus motif raising the possibility that the actual initiation sequence may not be included in this cDNA. The sphingosine kinase cDNA encodes for a protein (hSK) with a predicted isoelectric point of 6.64 and a molecular mass of 42,550 kDa, consistent with the molecular mass determined for the purified human placenta sphingosine kinase (SK1). Subcloning into pcDNA3 and transient expression of hSK in HEK293 cells resulted in a 3200-fold increase in sphingosine kinase activity in these cells (Fig. 8), compared with untransfected HEK293 cells or HEK293 cells transfected with empty vector, indicating that the generated hSK cDNA encodes a genuine sphingosine kinase. Interestingly, although hSK-transfected HEK293 cells had 3200-fold higher levels of sphingosine kinase activity, treatment of these cells with $\text{TNF}\alpha$ resulted in a rapid (10min) increase in sphingosine kinase activity by a similar proportion (approximately 2-fold) to that seen in untransfected HEK293 cells (Fig. 8) (Xia *et al.*, 1998). This indicates the high levels of over-expressed sphingosine kinase are not saturating the $\text{TNF}\alpha$ mediated activation mechanism in these cells.

EXAMPLES 8

HUMAN SPHINGOSINE KINASE ANALYSIS - RESULTS

[0119] A search of the database shown hSK has a high amino acid sequence similarity (28 to 36% identity) to two recently identified *Saccharomyces cerevisiae* sphingosine kinases (Nagiec *et al.*, 1998) and several other ESTs encoding putative sphingosine kinase proteins from *Schizosaccharomyces pombe*, *Caenorhabditis elegans* and *Arabidopsis thaliana*. Multiple sequence alignment of hSK with these homologues (Fig. 9) revealed several regions of highly conserved amino acids throughout the protein, but particularly towards the N-terminus.

[0120] A search of the domain structures of hSK sequence revealed three calcium/calmodulin binding motifs (Rhoads & Friedberg, 1997), one of the 1-8 14 type A ([FILVW]xxx[FAILVW]xx[FAILVW]xxxxx[FILVW] with net charge of +3 to +6) spanning residues 290 to 303, and two of the 1-8 14 type B ([FILVW]xxxxx[FAILVW]xxxxx[FILVW] with net charge of +2 to +4) that overlap between residues 134 to 153. Further analysis of the hSK sequence revealed a possible N-myristoylation site close to the N-terminus (at Gly⁵) that may be applicable if the protein is subject to proteolytic cleavage. Also identified were one putative casein kinase II (CKII) phosphorylation site (at Ser¹³⁰) and four putative PKC phosphorylation sites (at Thr⁵⁴, Ser¹⁸⁰, Thr²⁰⁵ and Ser³⁷¹) (Fig. 7). These putative phosphorylation sites are also found in both murine sphingosine kinase isoforms, although the mouse enzymes also display six more possible phosphorylation sites; four for PKC, and one each for CKII and protein kinase A, that do not occur in hSK.

[0121] A search of signalling domain sequences using the SMART search tool (Schultz *et al.*, 1998; Ponting *et al.*,

1999) revealed similarity in residues 16 to 153 of hSK to the putative diacylglycerol kinase (DGK) catalytic domain. hSK showed an overall 36% identity to the consensus sequence of the DGK catalytic domain family, and possessed 17 of the 24 very highly conserved amino acids of this domain. hSK, however, showed no homology with the proposed ATP binding motif of this domain (GxGxxG_nK), although it should be noted that the applicability of this protein kinase ATP-binding site motif (Hanks *et al.*, 1988) to DGKs remains contentious (Schaap *et al.*, 1994); Sakane *et al.*, 1996; Masai *et al.*, 1993). Further sequence analysis of the human sphingosine kinases also failed to find regions showing any marked similarity to the proposed nucleotide-binding motifs found in other protein families (Saraste *et al.*, 1990; Walker *et al.*, 1982). Apart from the similarity to the DGK catalytic domain, hSK shows no similarity to other lipid binding enzymes, and does not appear to have any recognizable lipid binding domains, like PKC C2 or pleckstrin homology domains. There are also no other obvious regulatory domains, with the possible exception of a proline-rich region at the C-terminus which has some similarity to SH3 binding domains (Ren *et al.*, 1993; Yu *et al.*, 1994).

EXAMPLE 9

EXPRESSION IN *E. COLI* AND ISOLATION OF RECOMBINANT SPHINGOSINE KINASE - RESULTS

[0122] The hSK cDNA was subcloned into the pGEX 4T-2 plasmid and hSK expressed as a glutathione s-transferase (GST) fusion protein in *E. coli* BL21 by IPTG induction (Fig. 10). After the GST-hSK fusion protein was partially purified using glutathione Sepharose 4B, and the GST removed by thrombin cleavage, the hSK was further purified by subsequent elutions from calmodulin Sepharose and Mono-Q anion exchange columns. This resulted in high recovery of sphingosine kinase activity (greater than 70% of the originally induced activity), and an electrophoretically pure sphingosine kinase (Fig. 10). However, only low protein yields of the recombinant enzyme could be obtained since a large proportion of the IPTG induced, thrombin-cleaved hSK protein did not bind to the calmodulin Sepharose column (Fig. 11). This non-binding form of hSK had no demonstrable catalytic activity, suggesting that it was incorrectly folded.

EXAMPLE 10

POST-TRANSLATIONAL MODIFICATION REQUIREMENT FOR SPHINGOSINE KINASE FUNCTIONAL ACTIVITY

[0123] To determine if post-translational modifications are required for activity of the native sphingosine kinase, the native molecule has been compared to the recombinant enzyme produced in *E. coli* where such modifications would not occur. Specifically, the enzymes have been examined for differences in substrate affinity and accessibility. The premise for this study was that post-translational modifications may cause conformational changes in the structure of sphingosine kinase which may result in detectable changes in the physico-chemical or catalytic properties of the enzyme. In summary, it was determined that recombinantly produced sphingosine kinase retains its functional activity even in the absence of post-translational modification.

METHODS

Substrate specificity of the native and recombinant sphingosine kinases

[0124] Relative rates of phosphorylation of sphingosine by the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU of the native and recombinant sphingosine kinases, respectively. The substrates examined were added to a final concentration of 100 μ M in 0.25% (w/v) Triton X-100, and assayed under the standard assay conditions outlined earlier.

Substrate and inhibitor kinetics of the native and recombinant sphingosine kinases

[0125] Substrate kinetics were determined by supplying substrates over the concentration range of 0.5 to 200 μ M for sphingosine analogues, and 5 to 1000 μ M for ATP. Inhibition kinetics were determined by the use of inhibitors over a concentration range of 2 to 50 μ M (Table 5). In both cases the data were analysed by non-linear regression.

Thermal stabilities of the native and recombinant sphingosine kinases

[0126] Thermal stabilities of the native and recombinant sphingosine kinases were determined by assaying the residual activity remaining after preincubation of the enzymes at various temperatures (4 to 80°C) for 30 min at pH 7.4 (50mM Tris/HCl containing 10% glycerol, 0.5M NaCl and 0.05% Triton X-100). The original activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively.

pH stabilities of the native and recombinant sphingosine kinases

[0127] pH stabilities of the native and recombinant sphingosine kinases were determined by assaying the residual activity remaining after preincubation of the enzymes at various pH's at 4°C for 5 hr. The original activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively.

The effect of pH on activity of the native and recombinant sphingosine kinases

[0128] The effect of pH on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity over the pH range of 4 to 11 in 50mM buffers (sodium acetate, pH 4.0-5.0; Mes, pH 6.0-7.0; Hepes, pH 7.0-8.2; Tris, pH 8.2-10.0; Caps, pH 10.0-11.0). The maximum activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively.

Effect of metal ions on the activity of the native and recombinant sphingosine kinases

[0129] The effect of metal ions on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity under standard conditions in the presence of various metal ions or EDTA at 10mM. The maximum activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively.

Effect of phospholipids on the activity of the native and recombinant sphingosine kinases

[0130] The effect of various phospholipids on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity under standard conditions in the presence of these phospholipids at 10 mol% of Triton X-100. The activities of the native and recombinant sphingosine kinases in the absence of phospholipids were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively. PC, phosphatidylcholine; PS phosphatidylserine; PE, phosphatidylethanolamine; PI, phosphatidylinositol.

RESULTS

[0131] Maximum activity of the native and recombinant sphingosine kinases were observed at pH 7.4, with both enzymes showing greater than 60% of maximum activity in the pH range 6.8 to 7.4 (Fig. 12). Both sphingosine kinases retained more than 90% of the original activity after 5 h incubation at 4°C in the pH range 6 to 7.8 (Fig. 12), and at pH 7.4 in the presence of 10% glycerol, 0.5M NaCl and 0.05% Triton X-100, both enzymes were stable for 30 min at temperatures up to 37°C (Fig. 12). The enzymes were much less stable in buffers lacking glycerol, NaCl and Triton X-100 (data not shown), consistent with previous observations of the bovine brain and rat kidney sphingosine kinases (Louie *et al.*, 1976; Olivera *et al.*, 1998). Both human sphingosine kinases showed a requirement for divalent metal ions since the presence of EDTA in assays eliminated activity (Fig. 12). Like other sphingosine kinases examined (Louie *et al.*, 1976; Buehrer & Bell, 1992; 1993; Olivera *et al.*, 1998; Nagiec *et al.*, 1998), both human enzymes showed highest activity with Mg²⁺, somewhat lower activity with Mn²⁺, and only very low activity with Ca²⁺. Other divalent metal ions examined, including Zn²⁺, Cu²⁺ and Fe²⁺, did not support sphingosine kinase activity (Fig. 12).

[0132] The native and recombinant sphingosine kinases have very similar, and narrow, substrate specificities (Fig. 13), with both showing greatest activity with the naturally occurring mammalian substrate D-erythro-sphingosine as well as D-erthro-dihydrosphingosine. Low activity was also detected for both enzymes against phytosphingosine, while a range of other sphingosine derivatives and related molecules were not phosphorylated. These included DL-threo-dihydrosphingosine, N,N-dimethylsphingosine, N,N,N-trimethylsphingosine, N-acetylsphingosine (C₂-ceramide), diacylglycerol (1,2-dioctanoyl-sn-glycerol and 1,2-dioleoyl-sn-glycerol), and phosphatidylinositol. Further analysis of the human sphingosine kinases with D-erythro-sphingosine as well as D-erthro-dihydrosphingosine revealed Michaelis-Menten kinetics over the concentration range used (Fig. 13), with both isolated native and recombinant sphingosine kinases showing very similar kinetic properties and slightly higher affinity for D-erythro-sphingosine as well as D-erthro-dihydrosphingosine (Table 5). Both enzymes also displayed similar kinetics when sphingosine was supplied as a sphingosine-BSA complex, although presentation of the substrate in this manner resulted in a lower k_{cat} values for both enzymes (28 s⁻¹ and 39 s⁻¹ for the native and recombinant sphingosine kinases, respectively) compared to its presentation in Triton X-100 mixed micelles, as used for all the other assays performed in this study. Sphingosine supplied as a BSA complex K_m values of 16 ± 4 mM and 17 ± 2 mM for the native and recombinant sphingosine kinases, respectively. Both the native and recombinant sphingosine kinases had the same affinity for ATP (K_m of approx. 80 mM (Table 5).

[0133] Both the native and recombinant sphingosine kinase were inhibited by DL-threo-dihydrosphingosine, N,N-dimethylsphingosine and N,N,N-trimethylsphingosine (Fig. 13), with all three of these molecules displaying com-

petitive inhibition with respect to sphingosine. Although the inhibition constants for these molecules were quite similar, *N,N,N*-trimethylsphingosine gave slightly more efficient inhibition than *DL-threo*-dihydrosphingosine, which was a marginally more efficient inhibitor than *N,N*-dimethylsphingosine (Table 5).

[0134] ADP also showed weak competitive inhibition, with respect to ATP (Table 5). In all cases remarkably similar inhibition constants were observed for the native and recombinant sphingosine kinases (Table 5). No inhibition was seen with *N*-acetylsphingosine or Fumosin B1, a ceramide synthase inhibitor.

[0135] The effect of calcium/calmodulin on sphingosine kinase activity was examined. Under the assay conditions used, calcium/calmodulin had no effect on the activity of either the native or recombinant human sphingosine kinases (data not shown). While this result indicates a lack of sphingosine kinase activity regulation by calmodulin, the possibility remains that calmodulin may be involved in some other function with sphingosine kinase, such as regulating its sub-cellular localisation.

[0136] Stimulation of sphingosine kinase activity by acidic phospholipids was examined. The addition of the neutral phospholipids phosphatidylcholine and phosphatidylethanolamine to the enzyme assay mixture did not result in any detectable differences in human sphingosine kinase activity, however, marked increases in activity (1.6 to 2-fold) were observed with the acidic phospholipids phosphatidylserine, phosphatidylinositol and phosphatidic acid (Fig. 14). Both the native and recombinant sphingosine kinases were activated in a similar manner by these acidic phospholipids, with kinetic analyses revealing that all three phospholipids caused an increase in the enzymes K_{cat} , while the K_m values remained unchanged.

[0137] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

Table 3 - Comparison of sphingosine kinase activity in human placenta with various animal tissues Fresh animal tissues were washed and homogenized as described for the human placenta. The proportion of cytosolic sphingosine kinase activity was determined by comparison of the total activity in the homogenate to that from the ultracentrifugation supernatant (100,000 x g, 60 min). The specific activity of sphingosine kinase is expressed as pmol of S1P formed per minute (U) per g tissue.

	Specific activity (U/g tissue)	Cytosolic (%)
Human placenta	13	51
Rat kidney	28	63
Rat liver	19	37
Rat brain	13	52
Sheep kidney	38	58
Sheep liver	17	31
Sheep brain	16	63
Sheep spleen	9	34

Table 4 - Purification of sphingosine kinase from human placenta Sphingosine kinase was purified from 1240 g of fresh human placenta (4 placentas). One unit (U) of sphingosine kinase activity is defined as 1 pmol of S1P formed from sphingosine and ATP per minute.

Step	Activity (U x 10 ³)	Protein (mg)	Specific Activity (U/mg)	Recovery (%)	Purification Fold
Soluble fraction of homogenate	7943	123600	58	100	
Ammonium sulphate (25-35%)	7723	3527	1966	97	33

(continued)

Step	Activity (U x 10 ³)	Protein (mg)	Specific Activity (U/mg)	Recovery (%)	Purification Fold
Q Sepharose anion exchange	4048	1098	4597	63	79
Calmodulin Sepharose	3197	18.23	1.75 x 10 ⁵	40	3.0 x 10 ³
Mono Q anion exchange	1706	2.921	5.84 x 10 ⁵	21.5	1.0 x 10 ⁴
ATP- Mono Q anion exchange	1133	0.419	2.70 x 10 ⁶	14.3	4.6 x 10 ⁴
Superdex 75 gel filtration	549	0.008	6.64 x 10 ⁷	6.9	1.1 x 10 ⁶

Table 5 - Substrate and inhibition kinetics of the native and recombinant sphingosine kinases Substrate kinetics were determined by supplying substrates over the concentration range of 0.5 to 200 μ M (0.0125 to 5 mol %) for sphingosine analogues, and 5 to 1000 μ M for ATP. Inhibition kinetics were determined by the use of inhibitors over a concentration range of 2 to 50 μ M (0.05 to 1.25 mol %) for sphingosine analogues and 0.1 to 5 mM for ADP. For comparison to previous studies, all K_m and K_i values for sphingosine and its derivatives are expressed as both bulk solution concentrations and mol % of Triton X- 100, where Triton X-100 was present in all assays at a final concentration of 0.25% (w/v). All kinetic values and standard errors (Duggleby, 1981) were obtained from non-linear regression analysis (Easterby, 1996).

	Native SK	Recombinant SK
SUBSTRATE KINETICS:		
Sphingosine		
K_m (mol %)	0.35 $\pm$ 0.05.	0.30 $\pm$ 0.07
$-K_m$ (μ M)	14 $\pm$ 2	12 $\pm$ 3
k_{cat} (S ⁻¹)	50	85
k_{cat}/K_m (10 ⁻⁵ S ⁻¹ .M ⁻¹)	36	71
Dihydrosphingosine		
K_m (mol %)	0.50 $\pm$ 0.05	0.48 $\pm$ 0.05
K_m (μ M)	20 $\pm$ 2	19 $\pm$ 2
k_{cat} (S ⁻¹)	35	76
k_{cat} / K_m (10 ⁻⁵ s ⁻¹ . M ⁻¹)	18	39
ATP		
K_m (μ M)	77 $\pm$ 11	86 $\pm$ 12
INHIBITOR KINETICS:		
<i>N,N</i> -dimethylsphingosine		
K_i (mol %)	0.20 $\pm$ 0.03	0.19 $\pm$ 0.02
K_i (μ M)	7.8 $\pm$ 1	7.5 $\pm$ 1
DL- <i>threo</i> -dihydrosphingosine		
K_i (mol %)		
K_i (μ M)	0.15 $\pm$ 0.02	0.14 $\pm$ 0.03
	3.9 $\pm$ 1	5.7 $\pm$ 1
<i>N,N,N</i> -trimethylsphingosine		

EP 1 192 247 B9

(continued)

	Native SK	Recombinant SK
K_i (mol %)		
K_i (μ M)	0.12 ± 0.03	0.10 ± 0.02
ADP	4.6 ± 1	3.8 ± 1
K_i (mM)	1.1 ± 0.3	0.9 ± 0.2

BIBLIOGRAPHY

[0138]

- Altschul, S.F., Gish, W., Miller, W., Meyer, E.W., and Lipman, D.J., (1990) J. Mol. Biol. 215:403-410
- Alessenko, A.V., (1998) Biochemistry 63 :62-68
- Bonner et al., (1973) J. Mol. Biol. 81:123
- Bradford, M.M., (1976) Anal. Biochem. 72:248-254
- Buehrer, B.M., and Bell, R.M., (1992) J. Biol. Chem. 267:3154-3159
- Buehrer, B.M., and Bell, R.M., (1993) Adv. Lipid Res. 26:59-67
- Buehrer, B.M., Bardes, E.S., and Bell, R.M., (1996) Biochim. Biophys. Acta 1303:233-242
- Culliver, O., Pirianov, G., Kleuser, B., Vanek, P.G., Coso, O.A., Gutkind, J.S., and Spiegel, S., (1996) Nature 381:800-803
- Douillard and Hoffman, Basic facts about hybridomas in Compendium of Immunology, Vol II ed. Schwartz (1981)
- Duggleby, R.G., (1981) Anal Biochem. 110:9-18
- Easterby, J.S., (1996) Hyper 1.1s: Hyperbolic Regression Analysis of Enzyme Kinetic Data. Liverpool University, Liverpool
- Graham, F.L., and van der Eb, A.J., (1973) Virology 54:536 -539
- Hanks, S.K., Quinn, A.M., and Hunter, T., (1988) Science 241:42-52
- Igarashi, Y., (1997) J. Biochem. 122:1080-1087
- Kohama, T., Olivera, A., Edsall, L., Nagiec, M.M., Dickson, R. and Spiegel, S., (1998) J. Biol. Chem. 273:23722-23728
- Kohler and Milstein., (1975) Nature 256:495-499
- Laemmli, U.K., (1970) Nature 227:680-685
- Louie, D.D., Kisic, A., and Schroepfer, G.J., (1976) J. Biol. Chem. 251:4557-4564
- Masai, I., Okazaki, A., Hosoya, T., and Hotta, Y., (1993) Proc. Natl. Acad. Sci. USA 90:11157-11161
- Melendez, A., Floto, R.A., Gillooly, D.J., Harnett, M.M. and Allen, J.M., (1998) J. Biol. Chem. 273:9393-9402
- Meyer zu Heringdorf, D., van Koppen, C.J. and Jakobs, K.H., (1997) FEBS Lett 410:34-38

Nagiec, M.M., Skrzypek, M., Nagiec, E.E., Lester, R.L., and Dickson, R.C., (1998) J. Biol. Chem. 273:19437-19442

Olivera, A. and Spiegel, S., (1993) Nature 365:557-560

Olivera, A., Kohama, T., Tu, Z., Milstein, S., and Spiegel, S., (1998) J. Biol. Chem. 273:12576-12583

Ponting, C.P., Schultz, J., Milpetz, P., and Bork, P., (1999) Nucleic Acids Res. 27:229-232

Ren, R., Mayer, B.J., Cicchetti, P., and Baltimore, D., (1993) Science 259:1157-1161

Rhoads, A.R., and Friedberg, F., (1997) FASEB J. 11:331-340

Sakane, F., Lai, M., Wada, I., Imai, S., and Kohoh, H., (1996) Biochem. J. 318:583-590

Saraste, M., Sibbald, P.R., and Wittinghofer, A., (1990) Trends Biochem. Sci. 15:430-434

Schaap, D., van der Wal, J., and van Blitterswijk, W., (1994) Biochem. J. 304:661-662

Schultz, J., Milpetz, F., Bork, P., and Ponting, C.P., (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864

Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., and Klenk, D.C., (1985) Anal. Biochem. 150:76-85

Spiegel, S., Culliver, O., Edsall, L., Kohama, T., Menzeleev, R., Olivera, A., Thomas, D., Tu, Z., Van Brocklyn, J. and Wang, F., (1998). Biochemistry (Mosc) 63:69-73

Walker, J.E., Saraste, M., Runswick, M.J., and Gray, N.J., (1982) EMBO J. 8:945-951

Wall, R.T., Harker, L.A., Quadracci, L.J., and Striker, G.E., (1978) J. Cell. Physiol. 96:203-213

Wessel, D., and Flügge, U.I., (1984) Anal. Biochem. 138:141-143

Xia, P., Gamble, J.R., Rye, K.-A., Wang, L., Hii, C.S.T., Cockerill, P., Khew-Goodall, Y., Bert, A.-G., Barter, P.J. and Vadas, M.A., (1998) Proc. Natl. Acad. Sci. USA 95:14196-14201

Yu, H., Chen, J.K., Feng, S., Dalgarno, D.C., Brauer, A.W., and Schreiber, S.L., (1994) Cell 76:933-945

SEQUENCE LISTING

[0139]

<110> Johnson & Johnson Research Pty. Limited

<120> Sphingosine Kinase Enzyme

<130> AHB/FP5966189

<140> EP 00926537.2

<141> 2000-05-12

<150> PCT/AU00/00457

<151> 2000-05-12

<150> AU PQ 0339

<151> 1999-05-13

<150> AU PQ 1504

<151> 1999-07-08

<160> 5

<170> PatentIn Ver. 2.0

5 <210> 1
 <211> 1205
 <212> DNA
 <213> mammalian

10 <220>
 <221> CDS
 <222> (33)..(1184)

15 <400> 1

```

gaattcggca cgaggagccg cgggtcgagg tt atg gat cca gcg ggc ggc ccc 53
                               Met Asp Pro Ala Gly Gly Pro
                               1                               5

20  cgg ggc gtg ctc ccg cgg ccc tgc cgc gtg ctg gtg ctg ctg aac ccg 101
   Arg Gly Val Leu Pro Arg Pro Cys Arg Val Leu Val Leu Asn Pro
           10                   15                   20

25  cgc ggc ggc aag ggc aag gcc ttg cag ctc ttc cgg agt cac gtg cag 149
   Arg Gly Gly Lys Gly Lys Ala Leu Gln Leu Phe Arg Ser His Val Gln
           25                   30                   35

30  ccc ctt ttg gct gag gct gaa atc tcc ttc acg ccg atg ctc act gag 197
   Pro Leu Leu Ala Glu Ala Glu Ile Ser Phe Thr Leu Met Leu Thr Glu
           40                   45                   50                   55

35  cgg cgg aac cac gcg cgg gag ctg gtg cgg tcg gag gag ctg ggc cgc 245
   Arg Arg Asn His Ala Arg Glu Leu Val Arg Ser Glu Glu Leu Gly Arg
           60                   65                   70

40  tgg gac gct ctg gtg gtc atg tct gga gac ggg ctg atg cac gag gtg 293
   Trp Asp Ala Leu Val Val Met Ser Gly Asp Gly Leu Met His Glu Val
           75                   80                   85

45  gtg aac ggg ctc atg gag cgg cct gac tgg gag acc gcc atc cag aag 341
   Val Asn Gly Leu Met Glu Arg Pro Asp Trp Glu Thr Ala Ile Gln Lys
           90                   95                   100

```

5	ccc ctg tgt agc ctc cca gca ggc tct ggc aac gcg ctg gca gct tcc Pro Leu Cys Ser Leu Pro Ala Gly Ser Gly Asn Ala Leu Ala Ala Ser 105 110 115	389
10	ttg aac cat tat gct ggc tat gag cag gtc acc aat gaa gac ctc ctg Leu Asn His Tyr Ala Gly Tyr Glu Gln Val Thr Asn Glu Asp Leu Leu 120 125 130 135	437
15	acc aac tgc acg cta ttg ctg tgc cgc cgg ctg ctg tca ccc atg aac Thr Asn Cys Thr Leu Leu Leu Cys Arg Arg Leu Leu Ser Pro Met Asn 140 145 150	485
20	ctg ctg tct ctg cac acg gct tcg ggg ctg cgc ctc ttc tct gtg ctc Leu Leu Ser Leu His Thr Ala Ser Gly Leu Arg Leu Phe Ser Val Leu 155 160 165	533
25	agc ctg gcc tgg ggc ttc att gct gat gtg gac cta gag agt gag aag Ser Leu Ala Trp Gly Phe Ile Ala Asp Val Asp Leu Glu Ser Glu Lys 170 175 180	581
30	tat cgg cgt ctg ggg gag atg cgc ttc act ctg ggc act ttc ctg cgt Tyr Arg Arg Leu Gly Glu Met Arg Phe Thr Leu Gly Thr Phe Leu Arg 185 190 195	629
35	ctg gca gcc ttg cgc act tac cgc ggc cga ctg gct tac ctc cct gta Leu Ala Ala Leu Arg Thr Tyr Arg Gly Arg Leu Ala Tyr Leu Pro Val 200 205 210 215	677
40	gga aga gtg ggt tcc aag aca cct gcc tcc ccc gtt gtg gtc cag cag Gly Arg Val Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln 220 225 230	725
45	ggc ccg gta gat gca cac ctt gtg cca ctg gag gag cca gtg ccc tct Gly Pro Val Asp Ala His Leu Val Pro Leu Glu Glu Pro Val Pro Ser 235 240 245	773
50	cac tgg aca gtg gtg ccc gac gag gac ttt gtg cta gtc ctg gca ctg His Trp Thr Val Val Pro Asp Glu Asp Phe Val Leu Val Leu Ala Leu 250 255 260	821
55	ctg cac tcg cac ctg ggc agt gag atg ttt gct gca ccc atg ggc cgc Leu His Ser His Leu Gly Ser Glu Met Phe Ala Ala Pro Met Gly Arg 265 270 275	869
60	tgt gca gct ggc gtc atg cat ctg ttc tac gtg cgg gcg gga gtg tct Cys Ala Ala Gly Val Met His Leu Phe Tyr Val Arg Ala Gly Val Ser 280 285 290 295	917
65	cgt gcc atg ctg ctg cgc ctc ttc ctg gcc atg gag aag ggc agg cat Arg Ala Met Leu Leu Arg Leu Phe Leu Ala Met Glu Lys Gly Arg His 300 305 310	965
70	atg gag tat gaa tgc ccc tac ttg gta tat gtg ccc gtg gtc gcc ttc Met Glu Tyr Glu Cys Pro Tyr Leu Val Tyr Val Pro Val Val Ala Phe 315 320 325	1013
75	cgc ttg gag ccc aag gat ggg aaa ggt atg ttt gca gtg gat ggg gaa Arg Leu Glu Pro Lys Asp Gly Lys Gly Met Phe Ala Val Asp Gly Glu 330 335 340	1061

EP 1 192 247 B9

5 ttg atg gtt agc gag gcc gtg cag ggc cag gtg cac cca aac tac ttc 1109
 Leu Met Val Ser Glu Ala Val Gln Gly Gln Val His Pro Asn Tyr Phe
 345 350 355

 tgg atg gtc agc ggt tgc gtg gag ccc ccg ccc agc tgg aag ccc cag 1157
 Trp Met Val Ser Gly Cys Val Glu Pro Pro Pro Ser Trp Lys Pro Gln
 360 365 370 375

10 cag atg cca ccg cca gaa gag ccc tta tgatctagag tcgacctgca g 1205
 Gln Met Pro Pro Pro Glu Glu Pro Leu
 380

15 <210> 2
 <211> 384
 <212> PRT
 <213> mammalian

20 <400> 2

25

30

35

40

45

50

55

EP 1 192 247 B9

	Met	Asp	Pro	Ala	Gly	Gly	Pro	Arg	Gly	Val	Leu	Pro	Arg	Pro	Cys	Arg	
	1				5					10					15		
5	Val	Leu	Val	Leu	Leu	Asn	Pro	Arg	Gly	Gly	Lys	Gly	Lys	Ala	Leu	Gln	
				20					25					30			
	Leu	Phe	Arg	Ser	His	Val	Gln	Pro	Leu	Leu	Ala	Glu	Ala	Glu	Ile	Ser	
			35					40					45				
10	Phe	Thr	Leu	Met	Leu	Thr	Glu	Arg	Arg	Asn	His	Ala	Arg	Glu	Leu	Val	
		50					55					60					
	Arg	Ser	Glu	Glu	Leu	Gly	Arg	Trp	Asp	Ala	Leu	Val	Val	Met	Ser	Gly	
	65					70					75					80	
15	Asp	Gly	Leu	Met	His	Glu	Val	Val	Asn	Gly	Leu	Met	Glu	Arg	Pro	Asp	
					85					90					95		
	Trp	Glu	Thr	Ala	Ile	Gln	Lys	Pro	Leu	Cys	Ser	Leu	Pro	Ala	Gly	Ser	
				100					105					110			
20	Gly	Asn	Ala	Leu	Ala	Ala	Ser	Leu	Asn	His	Tyr	Ala	Gly	Tyr	Glu	Gln	
			115					120					125				
	Val	Thr	Asn	Glu	Asp	Leu	Leu	Thr	Asn	Cys	Thr	Leu	Leu	Leu	Cys	Arg	
		130					135					140					
25	Arg	Leu	Leu	Ser	Pro	Met	Asn	Leu	Leu	Ser	Leu	His	Thr	Ala	Ser	Gly	
	145					150				155						160	
	Leu	Arg	Leu	Phe	Ser	Val	Leu	Ser	Leu	Ala	Trp	Gly	Phe	Ile	Ala	Asp	
				165					170					175			
30	Val	Asp	Leu	Glu	Ser	Glu	Lys	Tyr	Arg	Arg	Leu	Gly	Glu	Met	Arg	Phe	
			180						185					190			
	Thr	Leu	Gly	Thr	Phe	Leu	Arg	Leu	Ala	Ala	Leu	Arg	Thr	Tyr	Arg	Gly	
35			195				200						205				
	Arg	Leu	Ala	Tyr	Leu	Pro	Val	Gly	Arg	Val	Gly	Ser	Lys	Thr	Pro	Ala	
	210					215					220						
40	Ser	Pro	Val	Val	Val	Gln	Gln	Gly	Pro	Val	Asp	Ala	His	Leu	Val	Pro	

225 230 235 240
 Leu Glu Glu Pro Val Pro Ser His Trp Thr Val Val Pro Asp Glu Asp
 245 250 255
 Phe Val Leu Val Leu Ala Leu Leu His Ser His Leu Gly Ser Glu Met
 260 265 270
 Phe Ala Ala Pro Met Gly Arg Cys Ala Ala Gly Val Met His Leu Phe
 275 280 285
 Tyr Val Arg Ala Gly Val Ser Arg Ala Met Leu Leu Arg Leu Phe Leu
 290 295 300
 Ala Met Glu Lys Gly Arg His Met Glu Tyr Glu Cys Pro Tyr Leu Val
 305 310 315 320
 Tyr Val Pro Val Val Ala Phe Arg Leu Glu Pro Lys Asp Gly Lys Gly
 325 330 335
 Met Phe Ala Val Asp Gly Glu Leu Met Val Ser Glu Ala Val Gln Gly
 340 345 350
 Gln Val His Pro Asn Tyr Phe Trp Met Val Ser Gly Cys Val Glu Pro
 355 360 365
 Pro Pro Ser Trp Lys Pro Gln Gln Met Pro Pro Pro Glu Glu Pro Leu
 370 375 380

30
 <210> 3
 <211> 24
 <212> DNA
 <213> mammalian

35
 <400> 3
 cggaattccc agtcggccgc ggta 24

40
 <210> 4
 <211> 26
 <212> DNA
 <213> mammalian

45
 <400> 4
 tagaattcta ccgcggccga ctggct 26

50
 <210> 5
 <211> 52
 <212> DNA
 <213> mammalian

55
 <400> 5
 tagaattcac ttgtcatcgt cgtccttgta gtctaagggc tcttctggcg gt 52

Claims

1. An isolated nucleic acid molecule encoding a sphingosine kinase, the nucleic acid molecule comprising :

(a) the sequence of SEQ ID NO:1 ; or

(b) a sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:2 ; or a nucleotide sequence complementary to the sequence of (a) or (b).

2. An isolated sphingosine, Kinase protein comprising the amino add sequence of SEQ ID NO:2.

3. Use of an antagonist of a sphingosine kinase protein of claim 2 selected from the group consisting of antisense nucleic acids, antibodies, RNA, DNazymes and RNA aptamers in the manufacture of a medicament for the treatment of a disease **characterised by** sphingosine kinase activity.

4. Use according to claim 3 wherein the disease is selected from rheumatoid arthritis, asthma, atherosclerosis, meningitis, multiple sclerosis, septic shock, inflammation, cell proliferation and apoptosis.

Patentansprüche

1. Isoliertes Nucleinsäuremolekül, das für eine Sphingosin-Kinase kodiert, wobei das Nucleinsäuremolekül Folgendes umfasst:

(a) die Sequenz von Seq.-ID Nr. 1; oder

(b) eine Sequenz, die für ein Polypeptid mit der Aminosäuresequenz von Seq.-ID Nr. 2-kodiert;

oder eine zu der Sequenz von (a) oder (b) komplementäre Nucleotidsequenz.

2. Isoliertes Sphingosin-Kinase-Protein, umfassend die Aminosäuresequenz von Seq.-ID Nr. 2.

3. Verwendung eines Antagonisten eines Sphingosin-Kinase-Proteins nach Anspruch 2, ausgewählt aus der aus Antisense-Nucleinsäuren, Antikörpern, RNA, DNazymen und RNA-Aptameren bestehenden Gruppe, bei der Herstellung eines Medikaments zur Behandlung einer Erkrankung, die durch Sphingosin-Kinase-Aktivität gekennzeichnet ist.

4. Verwendung nach Anspruch 3, worin die Erkrankung aus rheumatoider Arthritis, Asthma, Atherosklerose, Meningitis, multipler Sklerose, septischem Schock, Entzündung, Zellproliferation und Apoptose ausgewählt ist.

Revendications

1. Molécule d'acide nucléique isolée codant pour une sphingosine kinase, la molécule d'acide nucléique comprenant:

(a) la séquence de SEQ ID NO: 1; ou

(b) une séquence codant pour un polypeptide ayant la séquence d'acides aminés de SEQ ID NO: 2;

ou une séquence de nucléotides qui est complémentaire à la séquence (a) ou (b).

2. Protéine de sphingosine kinase isolée comprenant la séquence d'acides aminés de SEQ ID NO: 2.

3. Utilisation d'un antagoniste d'une protéine de sphingosine kinase de la revendication 2 sélectionné dans le groupe consistant en acides nucléiques antisens, anticorps, ARN, ADNzymes et aptamères d'ARN dans la fabrication d'un médicament pour le traitement d'une maladie **caractérisée par** une activité de sphingosine kinase.

4. Utilisation selon la revendication 3 où la maladie est sélectionnée parmi arthrite rhumatoïde, asthme, athérosclérose, méningite, sclérose en plaques, choc septique, inflammation, prolifération des cellules et apoptose.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

Cloning of HUVEC SK




Figure 6




Figure 7a

```

1      M D P A G G P R G V L P R P C R V L V 19
1      gagcgcgggtcgaggttatggatccagcggggcccccggggcggtgctcccgccgcccctgcccgcgtgctggtg 75

20     L L N P R G G K A L Q L F R S H V Q P L L A E 44
76     CTGCTGAACCCGCGCGGCAAGGCGCTTGACGCTCTCCGGAGTCACGTGCAGCCCCCTTTTGGCTGAG 150

45     A E I S F T L M L T E R R N H A R E L V R S E E L 69
151    GCTGAAATCTCCTTACGCTGATGCTACTAGCGGGCGGAACCCACGCGGGAGCTGGTGGTGGAGGAGCTG 225

70     G R W D A L V V M S G D G L M H E V V N G L M E R 94
226    GGCCGCTGGGACGCTCTGCTGTGATGCTGGAGACGGGCTGATGCACGAGGTGGTGAACGGGCTCATGGAGCGG 300

95     P D W E T A I Q K P L C S L P A G S G N A L A A S 119
301    CCTGACTGGGAGACCGCCATCCAGAAGCCCCCTGTGTAGCCTCCACGAGGCTCTGGCAACGCGCTGGCAGCTTCC 375

120    L N H Y A G Y E Q V T N E D L L T N C T L L L C R 144
376    TTGAACCATTTATGCTGGCTATGAGCAGGTCAACCAATGAAGACCTCCTGTACCAACTGCACGCTATTGCTGTGCCGC 450

145    R L L S P M N L L S L H T A S G L R L F S V L S L 169
451    CGGCTGCTGTACCCCATGAACCTGTCTCTGCACACGGCTTCGGGGCTGGCCCTCTTCTCTGTGCTCAGCCTG 525

170    A W G F I A D V D L E S E K Y R R L G E M R F T L 194
526    GCCTGGGGCTTCATGCTGATGTGGACCTAGAGAGTGAGAAGTATCGGCGTCTGGGGGAGATCGCGCTTCACTCTG 600

```

Figure 7a(i)

```

195 G T F L R L A A L R T Y R G R L A Y L P V G R V G 219
601 GGCACCTTCCCTGCGTCTGGCAGCCTTGCGCACTTACCGCGCGCGACTGGCTTACCTCCCTGTAGGAAGAGTGGGT 675

220 S K T P A S P V V V Q Q G P V D A H L V P L E E P 244
676 TCCAAGACACCTGCCCTCCCGTGTGTCCAGCAGGCGCGGTAGATGCACACCTTGTGCCACTGGAGGAGCCA 750

245 V P S H W T V V P D E D F V L V L A L L H S H L G 269
751 GTGCCCTCTCACTGGACAGTGGTGCCCGACGAGGACTTGTGCTAGTCTCTGGCACTGCTGCACCTCGCACCTGGGC 825

270 S E M F A A P M G R C A A G V M H L F Y V R A G V 294
826 AGTGAGATGTTTGCTGCACCCCATGGGCGCGCTGTGCAGCTGGCGTCATGCATCTGTTCTACGTGCGGGGAGTG 900

295 S R A M L L R L F L A M E K G R H M E Y E C P Y L 319
901 TCTCGTGCCATGCTGCTGCGCCTCTTCTTGCCCATGGAGAGGGCAGGCATATGGAGTATGAATGCCCCCTACTTG 975

320 V Y V P V V A F R L E P K D G K G M F A V D G E L 344
976 GTATATGTGCCCGTGGTCCGCTTCCGCTTGGAGCCCAAGGATGGAAAGGTATGTTGCAGTGGATGGGAATTG 1050

345 M V S E A V Q G Q V H P N Y F W M V S G C V E P P 369
1051 ATGGTTAGCGAGGCCGTCAGGCGCCAGGTGCACCCAACTACTTCTGGATGGTTCAGCGGTTGCGTGGAGCCCCCG 1125

370 P S W K P Q Q M P P P E E P L . 384
1126 CCCAGCTGGAAGCCCCCAGCAGATGCCACCGCCAGAGAGCCCCCTTatga 1173

```

Figure 7a(ii)




Figure 7b




Figure 8




Figure 9

hSK 1MDPAGGPRGVLP~~PR~~PCRVL~~V~~LLNP~~RG~~GKGKALQ~~L~~ERSHVQ~~P~~LLAEAEIS
 mSK1a 1MEPECPRGLLP~~PR~~PCRVL~~V~~LLNP~~QG~~GKGKALQ~~L~~FQSRVQ~~P~~FL~~EE~~AEIT
 mSK1b 1 MWCCVL.FVVECP~~RG~~LLP~~PR~~PCRVL~~V~~LLNP~~QG~~GKGKALQ~~L~~FQSRVQ~~P~~FL~~EE~~AEIT
 Yeast LCB4 206 NISSGTVEEILEKSYENS~~KR~~NR~~S~~IL~~V~~IINPH~~GG~~KG~~GT~~AKN~~L~~FLTKAR~~P~~ILVESGCK
 Yeast LCB5 252 DL...VEEILKRSYKN~~TR~~NR~~K~~SIF~~V~~IINP~~FG~~GKGKAK~~K~~L~~E~~MTKAK~~P~~LLASRCS
 S. pombe 90FCEYLLDVAYKGI~~KR~~SR~~R~~F~~I~~FINP~~HG~~GKGKAK~~K~~HIWESEAE~~P~~VFSSAHSI
 C. elegans 63 ENEQLTSVILSRKPP~~QE~~CRGN~~L~~LVFINP~~NS~~GTGKSLE~~T~~EANTVG~~PK~~LDKSLIR
 Consensus*.....R...*V.*NP.GGKGKA...*F.*...P.L...*...

hSK 112 SGNA~~LA~~ASLNHYAGYEQVTNEDLLTNCT~~L~~LLCRR...LLSP~~M~~NLLSLHTASGLRL
 mSK1a 111 SGNA~~LA~~ASVNHYAGYEQVTNEDLLINCT~~L~~LLCRR...RLSP~~M~~NLLSLHTASGLRL
 mSK1b 118 SGNA~~LA~~ASVNHYAGYEQVTNEDLLINCT~~L~~LLCRR...RLSP~~M~~NLLSLHTASGLRL
 Yeast LCB4 325 SGNA~~MS~~IS.....CHWTNNPSYAALCLVK~~S~~IE~~T~~RIDLMCCSQPSYMNEWPR
 Yeast LCB5 368 SGNA~~MS~~VS.....CHWTNNPSYSTCLIK~~S~~IE~~T~~RIDLMCCSQPSYAREHPK
 S. pombe 203 SGNA~~FS~~YN.....ATGQLKPALTA~~L~~EILKGRPT~~S~~FDL~~M~~TFEQ...KGKKA
 C. elegans 184 SGNGLLC~~SV~~..LSKYGT~~K~~MNEKSVMERAL~~E~~IATSP~~T~~AKAESVALYSVKTDNQ.SY
 Consensus SGNA*..S.....*L.*.....*M.....

Figure 9(i)

hSK	211	AYLP.....	VGRVGSKTPASPVVVQQGPVD
mSK1a	210	AYLP.....	VGTVASKRPAST.LVQKGPVD
mSK1b	217	AYLP.....	VGTVASKRPAST.LVQKGPVD
Yeast LCB4	435	ENKDKNKGCLTFEP...NPSNPSSPDLLSKNNINNSTKDE.....	
Yeast LCB5	478	EH..KNKGSLEFQHITMKNKDCDNYNYENEYETENEDEDADADEDSHLIS	
S. pombe	308	EKSKNLAPMSESSDSK.....	
C. elegans	284	TYRYPYKPKGFHPSSNVFVYEKTTQQRIDDSKVKTNGSVSDSEETME	
Consensus		*	
hSK	282	AGVMHLFYV..RAGVSRAMLRLRLFLAMEKGRHMEYECFYL VYVPVAVFRLEPKDG	
mSK1a	280	AGVMHLFYV..RAGVSRAMLRLRLFLAMQKGMELDCPYLVHVPVAVFRLEPRSQ	
mSK1b	287	AGVMHLFYV..RAGVSRAMLRLRLFLAMQKGMELDCPYLVHVPVAVFRLEPRSQ	
Yeast LCB4	532	DGTIDLVTDAVIPVTR..MTPILLSLDKGS..VLEPEVIHSKILAYKIIIPKVE	
Yeast LCB5	586	DGTMDMVIDTARTSLTR..MAPILLGLDKGS..VLQPEVLHSKILAYKIIIPKLG	
S. pombe	367	DGLIDVIVIVYSKQFRKS..LLSMFTQLDNGGF..YYSKHLNYYKVRFRFTPVNT	
C. elegans	388	DNRIHLSYILWKDIGTRVNIAYKYLAIIEHETELDL..PFVVKHVEVSSMKLEVISE	
Consensus		.G.*.*.*.*.*R.*.*.*L**..G.H.....P.*.*.*.*.*P....	

Figure 9(ii)

```

FTLMLTERRNHARE.LVRSEELGRWDALVMSGDGLMHHEVUNGLMERPDWETAQKPLCSLPAG
FKLILTERKNHARE.LVCAEELGHWDALAVMSGDGLMHHEVUNGLMERPDWETAQKPLCSLPAG
FKLILTERKNHARE.LVCAEELGHWDALAVMSGDGLMHHEVUNGLMERPDWETAQKPLCSLPAG
IEIAYTKYARHAID.IAKDLDISKYDTIACASGDGIPYEVIINGLYRRPDVRDAFNKLAVTQLPCG
IEVYTKYPCHAIE.IAREMDIDKYDTIACASGDGIPHEVIINGLYQRPDHVKAFFNNAITEIPCG
CEVLTTRKDHAKS.IAKNLDVGSYDGILSVGGDGLFHEVIINGLYGERDDYLEAF.KLPVCMIPCG
YEVVVTGPNHARNVMTKADLGKFNGLVILSGDGLVFEALNGILCREDAFRIFPTLPIGIVEPSG
..**T...HA..**...***D...SGDG*..EV*NGL..R.D...A...**...*P.G

FSVLSLAWGFIADVDLESEKYYR.LGEMRFTLSTFLRLAALRTYRGRL.....
YSVLSLSWGFVADVDLESEKYYR.LGEIRFTVGTFFRLASLRIYQGQL.....
YSVLSLSWGFVADVDLESEKYYR.LGEIRFTVGTFFRLASLRIYQGQL.....
LSFLSQTYGVIAESDINTE.FIRWMGPVRFNLGVAFNI IQGKKYPCFVFVKYAAKSKKELKVHFL
LSFLSQTYGLIAETDINTE.FIRWMGPARELGVAFNI IQKKKYPCFVIYVKYAAKSKNELKNHYL
YSFLTANYGIIADCDIGTE.NWRFMGENRAYLGFFFLRFQKPDWKCSIEMDVVSSDRTEIKHMY.
ASFLSIGWGLMADIDIDSEKWRKSLGHHRFTVMGFIRSCNLRSYKGRL.....
.S.LS.**G.*A.D***E.*R.*G..RF.*G...*Y...*.....

```

Figure 9(iii)

```

AHLVPLEEPVPSHW.....TVVPD.....EDFVLVLALLHSHLGSEMFAPMGRCA
THLVPLEEPVPSHW.....TVVPE.....QDFVLVLVLLHSHLSSELFAPMGRCE
THLVPLEEPVPSHW.....TVVPE.....QDFVLVLVLLHSHLSSELFAPMGRCE
....LSPNFLNEDNFKLKYPMTEPVPRDWKMDSELTDNLTIFYTGKMPYIAKDTKFFPAALPA
RDLADSSADQIKEEDFKIKYPLDEGIPSDWERLDPNISNNLGIFYTGKMPYVAADTKFFPAALPS
.....TVSTSPESHLLTFEI.NDLSIFCAGLLPYIAPDAKMFPAASND
TKFQNWTLPDSDETLAVGSSDLEETVIE.....DNFVNIYAVTLSHIAADGPFAPSAKLE
.....**.....**.....*.....*.....*.....*.....*.....P.....
KG..MFAVDGELMVSEAVQGVHNYFW.MVSGCVEPPPSWKPQQMPPEEPL identity
RG..VFSVDGELMVC EAVQGVHNYLW.MVCGSRDAPSGRDSRRGPPPEEP. 81%
RG..VFSVDGELMVC EAVQGVHNYLW.MVCGSRDAPSGRDSRRGPPPEEP. 80%
SG..LFSVDGEEKFPLEPLQVEIMPLCKTLNRNGRYIDTEFESM..... 28%
NG..LFSVDGEEKFPLEPLQVEIMPLCKTLNRNGRYVDTDFDSM..... 30%
GKRHYFALDGEYSYPLEPFECRVA PKLGTLSPVAGFQLLDI..... 30%
GS..HVVL DGEVVDTKTIEVASTKNHIS.VFSSTA..... 30%
....F**DGE....E***.P.....*.....*.....*.....*.....*.....

```

Figure 9(iv)




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- EP 00926537 A [0139]
- AU 0000457 W [0139]

Non-patent literature cited in the description

- Basic Facts about Hybridomas. **DOUILLARD ; HOFFMAN**. Compendium of Immunology. 1981, vol. II [0092]
- **KOHLER ; MILSTEIN**. *Nature*, 1975, vol. 256, 495-499 [0092] [0138]
- *European Journal of Immunology*, 1976, vol. 6, 511-519 [0092]
- **ALTSCHUL, S.F. ; GISH, W. ; MILLER, W. ; MEYER, E.W. ; LIPMAN, D.J.** *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0138]
- **ALESSENKO, A.V.** *Biochemistry*, 1998, vol. 63, 62-68 [0138]
- **BONNER et al.** *J. Mol. Biol.*, 1973, vol. 81, 123 [0138]
- **BRADFORD, M.M.** *Anal. Biochem.*, 1976, vol. 72, 248-254 [0138]
- **BUEHRER, B.M. ; BELL, R.M.** *J. Biol. Chem.*, 1992, vol. 267, 3154-3159 [0138]
- **BUEHRER, B.M. ; BELL, R.M.** *Adv. Lipid Res.*, 1993, vol. 26, 59-67 [0138]
- **BUEHRER, B.M. ; BARDES, E.S. ; BELL, R.M.** *Biochim. Biophys. Acta*, 1996, vol. 1303, 233-242 [0138]
- **CULLIVER, O. ; PIRIANOV, G. ; KLEUSER, B. ; VANEK, P.G. ; COSO, O.A. ; GUTKIND, J.S. ; SPIEGEL, S.** *Nature*, 1996, vol. 381, 800-803 [0138]
- **DOUILLARD ; HOFFMAN**. *Basic facts about hybridomas in Compendium of Immunology*, 1981, vol. II [0138]
- **DUGGLEBY, R.G.** *Anal Biochem.*, 1981, vol. 110, 9-18 [0138]
- **EASTERBY, J.S.** *Hyper 1.1s: Hyperbolic Regression Analysis of Enzyme Kinetic Data.*, 1996 [0138]
- **GRAHAM, F.L. ; VAN DER EB, A.J.** *Virology*, 1973, vol. 54, 536-539 [0138]
- **HANKS, S.K. ; QUINN, A.M. ; HUNTER, T.** *Science*, 1988, vol. 241, 42-52 [0138]
- **IGARASHI, Y.** *J. Biochem.*, 1997 [0138]
- **KOHAMA, T. ; OLIVERA, A. ; EDSALL, L. ; NAGIEC, M.M. ; DICKSON, R. ; SPIEGEL, S.** *J. Biol. Chem.*, 1998, vol. 273, 23722-23728 [0138]
- **LAEMMLI, U.K.** *Nature*, 1970, vol. 227, 680-685 [0138]
- **LOUIE, D.D. ; KISIC, A. ; SCHROEPFER, G.J.** *J. Biol. Chem.*, 1976, vol. 251, 4557-4564 [0138]
- **MASAI, I. ; OKAZAKI, A. ; HOSOYA, T. ; HOTTA, Y.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 11157-11161 [0138]
- **MELENDEZ, A. ; FLOTO, R.A. ; GILLOOLY, D.J. ; HARNETT, M.M. ; ALLEN, J.M.** *J. Biol. Chem.*, 1998, vol. 273, 9393-9402 [0138]
- **MEYER ZU HERINGDORF, D. ; KOPPEN, C.J. ; JAKOBS, K.H.** *FEBS Lett*, 1997, vol. 410, 34-38 [0138]
- **NAGIEC, M.M. ; SKRZYPEK, M. ; NAGIEC, E.E. ; LESTER, R.L. ; DICKSON, R.C.** *J. Biol. Chem.*, 1998, vol. 273, 19437-19442 [0138]
- **OLIVERA, A. ; SPIEGEL, S.** *Nature*, 1993, vol. 365, 557-560 [0138]
- **OLIVERA, A. ; KOHAMA, T. ; TU, Z. ; MILSTEIN, S. ; SPIEGEL, S.** *Biol. Chem.*, 1998, vol. 273, 12576-12583 [0138]
- **PONTING, C.P. ; SCHULTZ, J. ; MILPETZ, J. ; BORK, P.** *Nucleic Acids Res.*, 1999, vol. 27, 229-232 [0138]
- **REN, R. ; MAYER, B.J. ; CICCHETTI, P. ; BALTIMORE, D.** *Science*, 1993, vol. 259, 1157-1161 [0138]
- **RHOADS, A.R. ; FRIEDBERG, F.** *FASEB J.*, 1997, vol. 11, 331-340 [0138]
- **SAKANE, F. ; LAI, M. ; WADA, I. ; IMAI, S. ; KOHOH, H.** *Biochem. J.*, 1996, vol. 318, 583-590 [0138]
- **SARASTE, M. ; SIBBALD, P.R. ; WITTINGHOFFER, A.** *Trends Biochem. Sci.*, 1990, vol. 15, 430-434 [0138]
- **SCHAAP, D. ; WAL, J. ; BLITTERSWIJK, W.** *Biochem. J.*, 1994, vol. 304, 661-662 [0138]
- **SCHULTZ, J. ; MILPETZ, F. ; BORK, P. ; PONTING, C.P.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 5857-5864 [0138]
- **SMITH, P.K. ; KROHN, R.I. ; HERMANSON, G.T. ; MALLIA, A.K. ; GARTNER, F.H. ; PROVENZANO, M.D. ; FUJIMOTO, E.K. ; GOEKE, N.M. ; OLSON, B.J. ; KLENK, D.C.** *Anal. Biochem.*, 1985, vol. 150, 76-85 [0138]
- **SPIEGEL, S. ; CULLIVER, O. ; EDSALL, L. ; KOHAMA, T. ; MENZELEE, R. ; OLIVERA, A. ; THOMAS, D. ; TU, Z. ; VAN BROCKLYN, J. ; WANG, F.** *Biochemistry (Mosc)*, 1998, vol. 63, 69-73 [0138]

EP 1 192 247 B9 (W1B1)

- **WALKER, J.E. ; SARASTE, M. ; RUNSWICK, M.J. ; GRAY, N.J.** *EMBO J.*, 1982, vol. 8, 945-951 [0138]
- **WALL, R.T. ; HARKER, L.A. ; QUADRACCI, L.J. ; STRIKER, G.E.** *J. Cell. Physiol.*, 1978, vol. 96, 203-213 [0138]
- **WESSEL, D. ; FLÜGGE, U.I.** *Anal. Biochem.*, 1984, vol. 138:, 141-143 [0138]
- **XIA, P. ; GAMBLE, J.R. ; RYE, K.-A. ; WANG, L. ; HUI, C.S.T. ; COCKERILL, P. ; KHEW-GOODALL, Y. ; BERT, A-G. ; BARTER, P.J. ; VADAS, M.A.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 14196-14201 [0138]
- **YU, H. ; CHEN, J.K ; FENG, S. ; DALGARN, D.C. ; BRAUER, A.W. ; SCHREIBER, S.L.** *Cell*, 1994, vol. 76, 933-945 [0138]